Abstract
Background
The placebo response in patients with diabetes mellitus is very common. A systematic evaluation needs to be updated with the current evidence about the placebo response in diabetes mellitus and the associated factors in clinical trials of anti-diabetic medicine.
Methods
Literature research was conducted in Medline, Embase, the Cochrane Central Register of Controlled Trials, and ClinicalTrials.gov for studies published between the date of inception and June 2019. Randomized placebo-controlled trials conducted in type 1and type 2 diabetes mellitus (T1DM/T2DM) were included. Random-effects model and meta-regression analysis were accordingly used. This meta-analysis was registered in PROSPERO as CRD42014009373.
Results
Significantly weight elevation (effect size (ES) = 0.33 kg, 95% CI, 0.03 to 0.61 kg) was observed in patients with placebo treatments in T1DM subgroup while significantly HbA1c reduction (ES = − 0.12%, 95% CI, − 0.16 to − 0.07%) and weight reduction (ES = − 0.40 kg, 95% CI, − 0.50 to − 0.29 kg) were observed in patients with placebo treatments in T2DM subgroup. Greater HbA1c reduction was observed in patients with injectable placebo treatments (ES = − 0.22%, 95% CI, − 0.32 to − 0.11%) versus oral types (ES = − 0.09%, 95% CI, − 0.14 to − 0.04%) in T2DM (P = 0.03). Older age (β = − 0.01, 95% CI, − 0.02 to − 0.01, P < 0.01) and longer diabetes duration (β = − 0.02, 95% CI, − 0.03 to − 0.21 × 10−2, P = 0.03) was significantly associated with more HbA1c reduction by placebo in T1DM. However, younger age (β = 0.02, 95% CI, 0.01 to 0.03, P = 0.01), lower male percentage (β = 0.01, 95% CI, 0.22 × 10−2, 0.01, P < 0.01), higher baseline BMI (β = − 0.02, 95% CI, − 0.04 to − 0.26 × 10−2, P = 0.02), and higher baseline HbA1c (β = − 0.09, 95% CI, − 0.16 to − 0.01, P = 0.02) were significantly associated with more HbA1c reduction by placebo in T2DM. Shorter diabetes duration (β = 0.06, 95% CI, 0.06 to 0.10, P < 0.01) was significantly associated with more weight reduction by placebo in T2DM. However, the associations between baseline BMI, baseline HbA1c, and placebo response were insignificant after the adjusted analyses.
Conclusion
The placebo response in diabetes mellitus was systematically outlined. Age, sex, disease severity (indirectly reflected by baseline BMI and baseline HbA1c), and disease duration were associated with placebo response in diabetes mellitus. The association between baseline BMI, baseline HbA1c, and placebo response may be the result of regression to the mean.
Similar content being viewed by others
Background
A placebo is defined as any therapy that is used for its non-specific psychological and physiologic effect, but has no demonstrated pharmacological effect on the condition being treated [1]. Pharmaceutical and clinical studies have used placebos as a methodological tool to avoid bias, and also to evaluate the pure therapeutic effect of interventional therapies, aiming to avoid introducing ineffective or even harmful treatments into clinical practice [1,2,3,4]. Placebo effect is even promoted as a potential treatment modality in medicine [1,2,3].
According to the expert consensus statement in placebo research field, placebo response, defined as any health change after the administration of placebo, including natural history of a disease or fluctuation of symptoms, response biases, effects of co-interventions, or statistical regression to the mean, has been widely observed in many clinical trials [5]. In fact, an increase in the magnitude of placebo response without significant change in the efficacy outcomes with respect to effect size and success rate is an emerging pattern over time in trials of many conditions, such as depression [6], epilepsy [7], and also diabetes mellitus (DM) [8]. A placebo has been widely used in clinical research in both type 1 diabetes mellitus (T1DM) and type 2 diabetes mellitus (T2DM). For example, the results of the new treatment were compared with placebo to prove the effect on glucose and body weight control. The placebo response was also used to estimate sample size in placebo-controlled trials and to evaluate the true effect size in active-controlled studies or real-world observational studies without a placebo group.
As for T2DM, the placebo response was previously reported by Khan et al. by analyzing the data from the U.S. Food and Drug Administration approved between 1999 and 2015 [8]. However, considering the increasing magnitude of placebo response and expanding clinical trial data, placebo response in T2DM, in terms of both glycemic and weight control, needs to be further evaluated and updated. Placebo response in T1DM has still not been systematically evaluated. Moreover, the potential factors associated with placebo response that might include patient age, gender, disease duration, follow-up duration, and ways of medication delivery have not been fully investigated and delineated. Knowledge from such investigations might suggest potential predictors for placebo responders and inform more precise clinical study design that allow more efficient efficacy evaluation of medical intervention in subpopulation of diabetes.
Since nonpharmacological interventions including behavior modification and nutritional therapies also play a role in glucose control in diabetes management, placebo response and its features mediated by psychosocial context may be more likely to be revealed in DM, which makes it an ideal model to explore placebo response. Therefore, we utilized the data of randomized controlled trials (RCTs) in both T1DM and T2DM and performed a meta-analysis to comprehensively outline the placebo response in DM. We also conducted the analysis for associated factors to propose a featured placebo response pattern associated with patient-level and study-level characteristics.
Methods
Data sources and searches
A systemic literature search was conducted for the published studies in the following databases: Medline, Embase, the Cochrane Central Register of Controlled Trials (CENTRAL), and ClinicalTrials.gov website, from the inception of each databases until June 2019. A search strategy was performed by using the following terms: metformin (MET); sulfonylurea (SU); alpha glucosidase inhibitor (AGI); thiazolidinedione (TZD); pramlintide; dipeptidyl peptidase-4 (DPP-4) inhibitor; sodium-glucose cotransporter 2 (SGLT2) inhibitor; glucagon-like peptide-1 receptor agonist (GLP-1RA); T1DM; T2DM; placebo-controlled; RCTs; cardiovascular outcome and renal outcome. Searches were firstly performed in January 2014 and subsequently updated in December 2017 and June 2019. This meta-analysis was registered in PROSPERO as CRD42014009373.
Study selection
Studies were included in this meta-analysis if following criteria were met: (1) placebo-controlled, randomized trials; (2) trials in patients with T1DM and T2DM; and (3) trials with HbA1c level and body weight measured in both placebo and active treatment groups. The exclusion criteria were as follows: (1) trials in patients with gestational diabetes or pre-diabetes; (2) trials in which the anti-diabetic treatment in the placebo group could be changed during the period of study; (3) trials with active agent control; and (4) trials with cross-over study design.
Data extraction and quality assessment
Two investigators independently extracted data by using a standardized form. Information including author, publication year, patient age, and male percentage was obtained from each trial for both placebo and active treatment groups. Trials with placebo agents administered by oral route were grouped for oral placebo response, and trials with placebo agents administered by injection route were grouped for injectable placebo response. Any disagreement would be resolved by the discussion between two investigators under the supervision of a third independent investigator. By using the Cochrane instrument [9], we evaluated the quality of each RCT.
Data synthesis and analysis
Placebo response were evaluated as pooled effect size (ES) with 95% confidence intervals (CIs) of HbA1c and weight changes from baseline in placebo treatment group by synthesizing mean value with standard error. Higgins I2 statistics were used to evaluate the between-study heterogeneity. Random-effects model was used in the meta-analysis. Subgroup comparisons for pooled ES were performed within the framework of a meta-analysis. The associations of continuous variables with placebo response on HbA1c and weight changes, including age, male percentage, baseline BMI, baseline HbA1c, diabetes duration, and study duration, were calculated by meta-regression analysis. Since publication year is a discontinuous variable, the associations between it and placebo response on HbA1c as well as weight change were analyzed by ANOVA tendency test. Indirect comparisons between HbA1c reduction and elevation groups as well as between weight reduction and elevation groups were conducted by Mann-Whitney test. The results of indirect comparisons were expressed as median value with accompanying interquartile range (Q1, Q3).
Publication bias was evaluated by Egger’s test, with a P value > 0.05 indicating low risk of publication bias. Pool ES analyses and subgroup comparisons were conducted by Review Manager statistical software package (version 5.3, Nordic Cochrane Centre, Copenhagen, Denmark). Meta-regression analysis was performed by the STATA statistical software package (Version 11.0). Mann-Whitney test and ANOVA tendency analysis were conducted by SPSS software (SPSS 24.0. Armonk, NY: IBM Corp). We conducted this study according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines for conducting and reporting meta-analyses of RCTs.
Results
Overall characteristics
In all, 432 placebo-controlled clinical trials conducted in patients with DM were included, among which 41 trials were in T1DM with 4328 participants and 391 trials were in T2DM with 33,987 participants (Additional file 1: Figure S1). The baseline characteristics of enrolled RCTs were summarized in detail for T1DM (Additional file 1: Table S1) [10,11,12,13,14,15,16,17,18,19,20,21,22,23,24,25,26,27,28,29,30,31,32,33,34,35,36,37,38,39,40,41,42,43,44,45,46,47,48,49,50,51,52,53,54,55,56,57,58,59] and T2DM (Additional file 1: Table S2) [60,61,62,63,64,65,66,67,68,69,70,71,72,73,74,75,76,77,78,79,80,81,82,83,84,85,86,87,88,89,90,91,92,93,94,95,96,97,98,99,100,101,102,103,104,105,106,107,108,109,110,111,112,113,114,115,116,117,118,119,120,121,122,123,124,125,126,127,128,129,130,131,132,133,134,135,136,137,138,139,140,141,142,143,144,145,146,147,148,149,150,151,152,153,154,155,156,157,158,159,160,161,162,163,164,165,166,167,168,169,170,171,172,173,174,175,176,177,178,179,180,181,182,183,184,185,186,187,188,189,190,191,192,193,194,195,196,197,198,199,200,201,202,203,204,205,206,207,208,209,210,211,212,213,214,215,216,217,218,219,220,221,222,223,224,225,226,227,228,229,230,231,232,233,234,235,236,237,238,239,240,241,242,243,244,245,246,247,248,249,250,251,252,253,254,255,256,257,258,259,260,261,262,263,264,265,266,267,268,269,270,271,272,273,274,275,276,277,278,279,280,281,282,283,284,285,286,287,288,289,290,291,292,293,294,295,296,297,298,299,300,301,302,303,304,305,306,307,308,309,310,311,312,313,314,315,316,317,318,319,320,321,322,323,324,325,326,327,328,329,330,331,332,333,334,335,336,337,338,339,340,341,342,343,344,345,346,347,348,349,350,351,352,353,354,355,356,357,358,359,360,361,362,363,364,365,366,367,368,369,370,371,372,373,374,375,376,377,378,379,380,381,382,383,384,385,386,387,388,389,390,391,392,393,394,395,396,397,398,399,400,401,402,403,404,405,406,407,408,409,410,411,412,413,414,415,416,417,418,419,420,421,422,423,424,425,426,427,428,429,430,431,432,433,434,435,436,437,438,439,440,441,442,443,444,445,446,447,448,449,450] respectively. The risk of bias was evaluated by the Cochrane instrument. In T1DM, there were 5 RCTs with high risk and 18 RCTs with uncertain risk of selection bias for random sequence generation, 4 RCTs with high risk and 15 RCTs with uncertain risk of selection bias for allocation concealment, and 5 RCTs with high risk of attrition bias (Additional file 1: Table S3). In T2DM, there were 8 RCTs with high risk and 15 RCTs with uncertain risk of selection bias for random sequence generation, 5 RCTs with high risk and 21 RCTs with uncertain risk of selection bias for allocation concealment, 22 RCTs with uncertain risk of performance bias, 13 RCTs with uncertain risk of detection bias, 37 RCTs with high risk and 30 RCTs with uncertain risk of attrition bias, and 12 RCTs with uncertain risk of reporting bias (Additional file 1: Table S4). The publication bias was accessed by Egger’s test in T1DM (t = − 0.29, P = 0.771) (Additional file 1: Figure S2) and T2DM (t = − 1.34, P = 0.179) (Additional file 1: Figure S3) respectively, which both turned out to be insignificant.
Overall placebo response
According to the meta-analysis, placebo treatment was generally associated with significantly HbA1c reduction (ES = − 0.11%, 95% CI, − 0.15 to − 0.07%) and weight reduction (ES = − 0.30 kg, 95% CI, − 0.40 to − 0.20 kg) in patients with DM (Table 1). As for specific DM types, significantly weight elevation (ES = 0.33 kg, 95% CI, 0.03 to 0.61 kg) was observed in patients with placebo treatments in T1DM subgroup while significantly HbA1c reduction (ES = − 0.12%, 95% CI, − 0.16 to − 0.07%) and weight reduction (ES = − 0.40 kg, 95% CI, − 0.50 to − 0.29 kg) were observed in patients with placebo treatments in T2DM subgroup (Fig. 1). As for treatment design, significantly HbA1c elevation (ES = 0.08%, 95% CI, 0.01 to 0.16%) was shown in monotherapy subgroup while add-on therapy was significantly associated with HbA1c reduction (ES = − 0.20%, 95% CI, − 0.25 to − 0.15%). Furthermore, significantly weight reduction was observed in both monotherapy (ES = − 0.56 kg, 95% CI, − 0.73 to − 0.39 kg) and add-on therapy (ES = − 0.19 kg, 95% CI, − 0.32 to − 0.07 kg) subgroups (Table 1). However, no significant difference was revealed in placebo response from different treatment designs by subgroup comparisons in terms of HbA1c and weight change. In T1DM, significantly HbA1c reduction was observed in patients with injectable placebo treatment (Fig. 2). In T2DM, significantly HbA1c reduction and weight reduction were observed in both oral and injectable placebo treatment subgroups (Fig. 2). Moreover, the magnitude of HbA1c reduction was greater in patients with injectable placebo (ES = − 0.22%, 95% CI, − 0.32 to − 0.11%) treatment than oral ones (ES = − 0.09%, 95% CI, − 0.14 to − 0.04%, P for subgroup comparison = 0.03) (Table 1).
Placebo response stratified by hypoglycemic comparators
Placebo responses stratified by hypoglycemic comparators were also systematically summarized in Table 1. In T1DM, generally distinct degree of HbA1c reductions was observed in different active comparator subgroups except metformin and AGI subgroups (Fig. 3). Comparable weight elevations were observed in most subgroups except a mild weight reduction seen in AGI subgroup (Fig. 3). In T2DM, placebo in metformin, TZD, and SU subgroups conferred HbA1c elevation effect while HbA1c reductions were observed in AGI, SGLT2i, DPP-4i, and GLP-1RA subgroups (Fig. 3). Weight reductions were shown in all hypoglycemic agent subgroups in T2DM (Fig. 3). By subgroup comparisons, greater HbA1c reduction was observed in GLP-1RA subgroup versus metformin subgroup in T1DM (P = 0.01). In terms of T2DM, greater HbA1c reduction was observed in GLP-1RA subgroup versus metformin subgroup (P < 0.01) and TZD subgroup (P < 0.01) respectively (Table 1). Similarly, greater HbA1c reduction was observed in SGLT2i subgroup versus metformin subgroup (P < 0.01), TZD subgroup (P < 0.01), SU (P = 0.02) subgroup, and DPP-4i subgroup (P = 0.02) respectively (Table 1).
Associated factors with placebo response
Age
The HbA1c level with placebo treatments modestly increased in patients with T1DM below 18 years old (Additional file 1: Figure S4). However, this effect shifted into HbA1c reduction when the patients’ ages became older. Moreover, meta-regression analysis suggested older age was significantly associated with greater HbA1c reduction (β = − 0.01, 95% CI, − 0.02 to − 0.01, P < 0.01) (Fig. 4a). As for body weight, a profound increase with placebo treatments was found in T1DM patients under 18 (Additional file 1: Figure S4), but no specific changing tendency was observed later (Table 2).
Unlike T1DM, a profound HbA1c reduction with placebo treatments was observed in T2DM below 50 years old. Such effect grew milder along with growing ages and almost diminished in elderly over 60 (Additional file 1: Figure S5). With significantly younger patient ages in HbA1c reduction subgroup versus HbA1c elevation subgroup (Additional file 1: Table S5), meta-regression analysis suggested younger age was associated with more HbA1c reduction (β = 0.02, 95% CI, 0.01 to 0.03, P = 0.01) (Fig. 4b). Different degree reductions of body weight were shown in different age subgroups (Additional file 1: Figure S5) but no significant association was discovered.
Sex
In T2DM, HbA1c reduction with placebo treatment was more frequently observed in groups with lower male percentages (Additional file 1: Figure S6) and the male percentages in HbA1c reduction subgroup were significantly lower than those in HbA1c elevation subgroup (Additional file 1: Table S5). Meta-regression analysis consistently showed that a lower male percentage was significantly associated with more HbA1c reduction by placebo in T2DM (β = 0.01, 95% CI, 0.22 × 10−2 to 0.01, P < 0.01) (Fig. 4c). Although weight reduction was displayed in subgroups stratified by male percentage in T2DM (Additional file 1: Figure S6), no significant association was shown by meta-regression. Moreover, no significant association was found between male percentage and placebo response on HbA1c or weight change in T1DM (Additional file 1: Figure S7).
Baseline BMI
In T2DM, the HbA1c level with placebo treatment was decreased in patients with baseline BMI over 25 kg/m2 (Additional file 1: Figure S8). Accordingly, baseline BMI was significantly higher in patients with HbA1c reduction versus HbA1c elevation (Additional file 1: Table S5). Meta-regression further confirmed that higher baseline BMI was significantly associated with more HbA1c reduction (β = − 0.02, 95% CI, − 0.04 to − 0.26 × 10−2, P = 0.02) (Fig. 4d). However, the association turned to be negative after adjusted by age, male percentage, duration of diabetes, study duration, and baseline HbA1c (β = − 0.01, 95% CI, − 0.03 to 0.01, P = 0.41). Weight reductions were observed in different BMI strata with placebo treatments except for the subgroup over 35 kg/m2 (Additional file 1: Figure S8). Although baseline BMI was significantly lower in patients with weight reduction versus weight elevation (Additional file 1: Table S5), no specific response pattern was found for baseline BMI and weight change by meta-regression in T2DM. In T1DM, no significant association was found for BMI and placebo response on HbA1c or weight change (Additional file 1: Figure S9).
Baseline HbA1c
In T2DM, the HbA1c alteration mediated by placebo treatments was mild in patients with baseline HbA1c below 8.5%, but it reduced more when baseline HbA1c got higher (Additional file 1: Figure S10). The comparison for baseline HbA1c level between HbA1c reduction and elevation subgroups also confirmed a significantly higher baseline HbA1c level in patients with HbA1c reduction (Additional file 1: Table S5). Consistently, meta-regression analysis indicated that higher baseline HbA1c was significantly associated with greater HbA1c reduction by placebo in T2DM (β = − 0.09, 95% CI, − 0.16 to − 0.01, P = 0.02) (Fig. 4e). However, this association was insignificant after adjusted by age, male percentage, duration of diabetes, study duration, and baseline BMI (β = − 0.04, 95% CI, − 0.16 to 0.08, P = 0.52). As for weight change, no specific response pattern was observed in T2DM (Additional file 1: Figure S10), although a significant higher baseline HbA1c level was observed in patients with weight elevation versus weight reduction (Additional file 1: Table S5). No significant association was found between baseline HbA1c and HbA1c or weight change in T1DM (Additional file 1: Figure S11).
Diabetes duration
Placebo response on HbA1c reduction in T1DM was more profound in patients with diabetes duration between 10 and 30 years (Additional file 1: Figure S12) and a longer diabetes duration was significantly associated with greater HbA1c reduction by placebo (β = − 0.02, 95% CI, − 0.03 to − 0.21 × 10−2, P = 0.03) (Fig. 4f). With different extents of weight reduction observed in diabetes duration subgroups (Additional file 1: Figure S12), no significant association was observed in T1DM.
In T2DM, although moderate HbA1c reduction in placebo treatment was observed in strata of different diabetes duration (Additional file 1: Figure S13), no significant association was found. However, an attenuated magnitude of placebo response on weight reduction was exhibited with increasing diabetes duration (Additional file 1: Figure S13). With significantly shorter diabetes duration observed in patients with weight reduction versus weight elevation (Additional file 1: Table S5), meta-regression analysis suggested a shorter diabetes duration was significantly associated with more weight reduction by placebo (β = 0.06, 95% CI, 0.02 to 0.10, P < 0.01) (Fig. 4 g).
Study duration
In T1DM, modest HbA1c reduction and weight elevation were observed among most study duration strata (Additional file 1: Figure S14). As for T2DM, with the study duration increasing, tendencies of placebo response shifting from HbA1c elevation to HbA1c reduction and from weight reduction to weight gain were displayed (Additional file 1: Figure S15). However, no specific distribution pattern was supported by meta-regression analyses in both T1DM and T2DM.
Publication year
In T1DM, HbA1c level in placebo treatment groups was increased in 1990s but decreased afterwards while weight level was reduced first but increased after 2000 (Additional file 1: Figure S16). The absolute alteration values for HbA1c and weight both peaked in 2006–2010 (Additional file 1: Figure S16). In T2DM, HbA1c level in placebo treatment arms tended to elevate modestly from the baseline between 1990 and 2005 but to decrease after 2006 (Additional file 1: Figure S17). As for weight change, except for a relatively modest increase before 1990, the placebo treatments mostly resulted in weight reduction in T2DM (Additional file 1: Figure S17). However, although comparisons showed that publication years of studies with HbA1c elevation and weight elevation in placebo treatment arms were significantly earlier than those with HbA1c and weight reduction (Additional file 1: Table S5), no significant associations were shown by ANOVA tendency tests in both T1DM and T2DM.
Discussion
This meta-analysis delineated the placebo response in both T1DM and T2DM with data from over 400 RCTs with almost 40,000 participants. More importantly, we characterized the placebo response pattern associated with patient age, sex, disease duration, and possibly disease severity (indirectly reflected by baseline BMI and baseline HbA1c) in diabetes, which tries to raise researchers’ attention again to weighting important moderators and predictors in placebo response.
As is mentioned, placebo response includes all health changes that result after the administration of an inactive treatment, thus including natural history, spontaneous recovery, and regression to the mean [451, 452]. So far, underlying mechanisms of placebo response are not fully understood. Individual patient and clinician factors, mutual interactions, and treatment environment may also somehow influence the placebo response to different extent. As for DM, placebo response can be related to optimal dietary treatment [453,454,455,456], or increased physical activity [457, 458], or improved education and management [459, 460], or patients’ expectations [461], in addition to fluctuation of symptoms and regression to the mean.
In this meta-analysis, data of T1DM have been included for analysis for the first time. Interestingly, significantly weight elevation was observed in T1DM patients with placebo treatments while significantly HbA1c reduction and weight reduction were observed in T2DM patients with placebo treatments. Considering all included studies in T1DM were with insulin add-on treatments, such difference in placebo response may be due to the background administration of insulin in T1DM population. Furthermore, we differentiated the oral and injection route for drug administration and found injectable placebo led to more HbA1c reduction compared with oral types in T2DM. It was hypothesized that a stronger signal delivered by subcutaneous puncture stimuli might trigger a positive psychological feedback that enhanced the placebo response, for example, raising patients’ expectations towards treatment benefits. But further evidence was still needed.
Patient age has been shown to consistently affect placebo response with different clinical conditions. Evaluations across medicine found that younger age was associated with higher placebo response, predominantly in psychiatric conditions and internal medicine [462]. In our study, older age was associated with more HbA1c reduction with placebo treatments in T1DM while younger age was associated with more HbA1c reduction with placebo treatments in T2DM. Such difference may be explained by distinct patient age distribution in T1DM and T2DM. In T1DM, adolescences and youth may not be mature enough to understand the disease severity and properly stick to the management routine. With their ages growing, their increased knowledge of DM may help them understand and believe in positive effects from well-organized DM management. In T2DM, patients are generally at a relatively mature age with disease onset. When they get older, less confidence and enthusiasm towards treatments and higher chance of experiencing treatment failure are likely to minimize the placebo response in these patients.
Sex is a controversial moderator for placebo response. Systematic reviews from major medical areas (neurology, psychiatry and internal medicine) but not from diabetes showed that only in 3 analyses female sex was associated with a higher placebo response, indicating poor evidence for contribution of sex to placebo response [463, 464]. But still, Enck et al. proposed that placebo response was predominantly the result of a conditioning learning response in females while a verbal manipulating of expectancies in males [463]. As a supplement, we did discover the sex difference of placebo response in T2DM in terms of HbA1c reduction.
Disease severity is another important associated factor with placebo response. In fact, a positive relationship between disease severity and magnitude of placebo response was previously observed in osteoarthritis [464]. As indirect indicators of disease severity, we found higher baseline BMI and higher baseline HbA1c were significantly associated with more HbA1c reduction achieved by placebo in T2DM, which was different from Khan’s finding [8]. The inconsistence between our results and Khan’s results might be due to different databases for placebo-controlled trials and more complicated groups of add-on treatment in our study. However, such associations turned to be negative after adjusted by other baseline parameters, including age, sex, duration of diabetes, and baseline BMI or HbA1c, which might influence the outcomes. Therefore, the correlations between increased disease severity (baseline BMI and higher baseline HbA1c) and greater HbA1c reduction may be the result of regression to the mean, which is also commonly observed in placebo response. Further investigations are needed to assess the potential link between placebo response and disease severity.
Disease duration is accompanied with alterations of patients’ understanding of disease itself and treatments. The association between the shorter disease duration and the larger placebo response effect size has been reported in fibromyalgia [465]. Similarly, we observed a shorter diabetes duration associated with more weight reduction by placebo in T2DM. It is possibly related to increasing treatment inertia and worsening adherence to nonpharmacological interventions in patients with longer durations. Moreover, worsening interrupted internal environment and neuro-endocrine-immune regulatory network with longer disease duration may also make it harder for placebo response to manifest.
This meta-analysis also has several limitations. First, included studies have different inclusion criteria, various baseline characteristics, non-uniform outcome definitions, and variable sample sizes. These factors will lead to heterogeneity among studies in this meta-analysis. Second, we did not include unpublished trials in our meta-analysis. Published studies may have an inherent bias, as unpublished trials tend to have null effects. However, the reported data from such unpublished trials were likely to be incomplete, espacially for placebo treatment group, which makes it hard for the quality evaluation and subsequent analysis. Therefore, we decide to exclude such studies. Moreover, we cannot fully assess the manipulation of each trials. Uncertainty of possibly inadequate blinding, additional bias from clinicians, known as “placebo by proxy” [466], and influence from underestimated interactions between patients and clinicians may affect the interpretation of our results. In addition, as a meta-analysis, data of HbA1c and body weight change in placebo treatment group were used as the surrogate parameters, but not the data at patient-level, which would be more helpful to draw a conclusion. It is noted that the associations between baseline BMI, HbA1c, and placebo response are still not definite, since the adjusted meta-regression tuned out to be negative. The correlations between the baseline severity and placebo response observed in our meta-analysis may be the result of regression to the mean. Therefore, statistical outcomes for this part should be interpreted with caution. Also, since we did not include studies with untreated control, we could only evaluate the placebo response rather than placebo effect in DM. More investigations, especially studies with untreated control, are needed to accurately record and analyze the placebo response and even placebo effect in DM, and possibly better differentiate the effect of regression to the mean.
Conclusions
Placebo response in diabetes was systematically outlined in this meta-analysis. Age, sex, and disease duration were associated factors with placebo response in diabetes, which may require more considerations when designing and conducting placebo-controlled clinical trials in diabetes. Baseline disease severity was also associated with placebo response in diabetes, which is likely to be the result of the regression to the mean. More investigations are encouraged to further explore unique or even potentially generalized placebo response patterns in DM and a wider field of medicine concerning more diseases.
Availability of data and materials
All data generated or analyzed during this study are included in this article and its supplementary information files.
Abbreviations
- AGI:
-
Alpha glucosidase inhibitor
- ANOVA:
-
Analysis of variance
- BMI:
-
Body mass index
- CI:
-
Confidence interval
- DM:
-
Diabetes mellitus
- DPP-4:
-
Dipeptidyl peptidase-4
- ES:
-
Effect size
- GLP-1RA:
-
Glucagon-like peptide-1 receptor agonist
- INR:
-
Interquartile range
- MET:
-
Metformin
- RCT:
-
Randomized controlled trial
- SGLT2:
-
Sodium-glucose cotransporter 2
- SU:
-
Sulfonylurea
- T1DM:
-
Type 1 diabetes mellitus
- T2DM:
-
Type 2 diabetes mellitus
References
Shapiro AK. Semantics of the placebo. Psvchiatr Q. 1968;42:653–95.
Shapiro AP, Schwartz GE, Ferguson DCE, Redmond DP, Weiss SM. Behavioral methods in the treatment of hypertension. Ann Intern Med. 1977;86:626–36.
Kaptchuk TJ, Miller FG. Placebo effects in medicine. N Engl J Med. 2015;373(1):8–9.
Hróbjartsson A, Gøtzsche PC. Placebo interventions for all clinical conditions. Cochrane Database Syst Rev. 2010;20(1):CD003974.
Evers AM, Luana C, Charlotte B, et al. Implications of placebo and nocebo effects for clinical practice: expert consensus. Psychother Psychosom. 2018;87(4):204–10.
Khan A, FahlMar K, Faucett J, et al. Has the rising placebo response impacted antidepressant clinical trial outcome? Data from the US Food and Drug Administration 1987-2013. World Psychiatry. 2017;16:181–92.
Rheims S, Perucca E, Cucherat M, et al. Factors determining response to antiepileptic drugs in randomized controlled trials. A systematic review and meta-analysis. Epilepsia. 2011;52:219–33.
Khan A, Fahl Mar K, Schilling J, et al. Magnitude and pattern of placebo response in clinical trials of oral antihyperglycemic agents: data from the Food and Drug Administration 1999-2015. Diabetes Care. 2018;41(5):994–1000.
Higgins JPT, Altman DG, Gotzsche PC, et al. The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials. BMJ. 2011;343:d5928.
Anderson JJA, Couper JJ, Giles LC, Leggett CE, Gent R, Coppin B, et al. Effect of metformin on vascular function in children with type 1 diabetes: a 12-month randomized controlled trial. J Clin Endocrinol Metab. 2017;102(12):4448–56.
Codner E, Iniguez G, Lopez P, Mujica V, Eyzaguirre FC, Asenjo S, et al. Metformin for the treatment of hyperandrogenism in adolescents with type 1 diabetes mellitus. Horm Res Paediatr. 2013;80(5):343–9.
Hamilton J, Cummings E, Zdravkovic V, Finegood D, Daneman D. Metformin as an adjunct therapy in adolescents with type 1 diabetes and insulin resistance: a randomized controlled trial. Diabetes Care. 2003;26(1):138–43.
Jacobsen IB, Henriksen JE, Beck-Nielsen H. The effect of metformin in overweight patients with type 1 diabetes and poor metabolic control. Basic Clin Pharmacol Toxicol. 2009;105(3):145–9.
Lund SS, Tarnow L, Astrup AS, Hovind P, Jacobsen PK, Alibegovic AC, et al. Effect of adjunct metformin treatment in patients with type-1 diabetes and persistent inadequate glycaemic control. A randomized study. PLoS One. 2008;3(10):e3363.
Lund SS, Tarnow L, Astrup AS, Hovind P, Jacobsen PK, Alibegovic AC, et al. Effect of adjunct metformin treatment on levels of plasma lipids in patients with type 1 diabetes. Diabetes Obes Metab. 2009;11(10):966–77.
Libman IM, Miller KM, DiMeglio LA, Bethin KE, Katz ML, Shah A, et al. Effect of metformin added to insulin on glycemic control among overweight/obese adolescents with type 1 diabetes: a randomized clinical trial. JAMA. 2015;314(21):2241–50.
Meyer L, Bohme P, Delbachian I, Lehert P, Cugnardey N, Drouin P, et al. The benefits of metformin therapy during continuous subcutaneous insulin infusion treatment of type 1 diabetic patients. Diabetes Care. 2002;25(12):2153–8.
Nadeau KJ, Chow K, Alam S, Lindquist K, Campbell S, McFann K, et al. Effects of low dose metformin in adolescents with type I diabetes mellitus: a randomized, double-blinded placebo-controlled study. Pediatr Diabetes. 2015;16(3):196–203.
Nwosu BU, Maranda L, Cullen K, Greenman L, Fleshman J, McShea N, et al. A randomized, double-blind, placebo-controlled trial of adjunctive metformin therapy in overweight/obese youth with type 1 diabetes. PLoS One. 2015;10(9):e0137525.
Petrie JR, Chaturvedi N, Ford I, Hramiak I, Hughes AD, Jenkins AJ, et al. Metformin in adults with type 1 diabetes: design and methods of REducing with MetfOrmin Vascular Adverse Lesions (REMOVAL): an international multicentre trial. Diabetes Obes Metab. 2017;19(4):509–16.
Petrie JR, Chaturvedi N, Ford I, Brouwers M, Greenlaw N, Tillin T, et al. Cardiovascular and metabolic effects of metformin in patients with type 1 diabetes (REMOVAL): a double-blind, randomised, placebo-controlled trial. Lancet Diab Endocrinol. 2017;5(8):597–609.
Pitocco D, Zaccardi F, Tarzia P, Milo M, Scavone G, Rizzo P, et al. Metformin improves endothelial function in type 1 diabetic subjects: a pilot, placebo-controlled randomized study. Diabetes Obes Metab. 2013;15(5):427–31.
Sarnblad S, Kroon M, Aman J. Metformin as additional therapy in adolescents with poorly controlled type 1 diabetes: randomised placebo-controlled trial with aspects on insulin sensitivity. Eur J Endocrinol. 2003;149(4):323–9.
Ziaee A, Esmailzadehha N, Honardoost M. Comparison of adjunctive therapy with metformin and acarbose in patients with Type-1 diabetes mellitus. Pak J Med Sci. 2017;33(3):686–90.
Hollander P, Pi-Sunyer X, Coniff RF. Acarbose in the treatment of type I diabetes. Diabetes Care. 1997;20(3):248–53.
Riccardi G, Giacco R, Parillo M, Turco S, Rivellese AA, Ventura MR, et al. Efficacy and safety of acarbose in the treatment of type 1 diabetes mellitus: a placebo-controlled, double-blind, multicentre study. Diab Med. 1999;16(3):228–32.
Bhat R, Bhansali A, Bhadada S, Sialy R. Effect of pioglitazone therapy in lean type 1 diabetes mellitus. Diab Res Clin Pract. 2007;78(3):349–54.
Strowig SM, Raskin P. The effect of rosiglitazone on overweight subjects with type 1 diabetes. Diabetes Care. 2005;28(7):1562–7.
Tafuri KS, Godil MA, Lane AH, Wilson TA. Effect of pioglitazone on the course of new-onset type 1 diabetes mellitus. J Clin Res Pediatr Endocrinol. 2013;5(4):236–9.
Zdravkovic V, Hamilton JK, Daneman D, Cummings EA. Pioglitazone as adjunctive therapy in adolescents with type 1 diabetes. J Pediatr. 2006;149(6):845–9.
Ahren B, Hirsch IB, Pieber TR, Mathieu C, Gomez-Peralta F, Hansen TK, et al. Efficacy and safety of liraglutide added to capped insulin treatment in subjects with type 1 diabetes: the ADJUNCT TWO randomized trial. Diabetes Care. 2016;39(10):1693–701.
Dejgaard TF, Frandsen CS, Hansen TS, Almdal T, Urhammer S, Pedersen-Bjergaard U, et al. Efficacy and safety of liraglutide for overweight adult patients with type 1 diabetes and insufficient glycaemic control (Lira-1): a randomised, double-blind, placebo-controlled trial. Lancet Diab Endocrinol. 2016;4(3):221–32.
Dejgaard TF, Johansen NB, Frandsen CS, Asmar A, Tarnow L, Knop FK, et al. Effects of liraglutide on cardiovascular risk factors in patients with type 1 diabetes. Diabetes Obes Metab. 2017;19(5):734–8.
Frandsen CS, Dejgaard TF, Holst JJ, Andersen HU, Thorsteinsson B, Madsbad S. Twelve-week treatment with liraglutide as add-on to insulin in normal-weight patients with poorly controlled type 1 diabetes: a randomized, placebo-controlled, double-blind parallel study. Diabetes Care. 2015;38(12):2250–7.
Frandsen CS, Dejgaard TF, Andersen HU, Holst JJ, Hartmann B, Thorsteinsson B, et al. Liraglutide as adjunct to insulin treatment in type 1 diabetes does not interfere with glycaemic recovery or gastric emptying rate during hypoglycaemia: a randomized, placebo-controlled, double-blind, parallel-group study. Diabetes Obes Metab. 2017;19(6):773–82.
Kuhadiya ND, Dhindsa S, Ghanim H, Mehta A, Makdissi A, Batra M, et al. Addition of liraglutide to insulin in patients with type 1 diabetes: a randomized placebo-controlled clinical trial of 12 weeks. Diabetes Care. 2016;39(6):1027–35.
Mathieu C, Zinman B, Hemmingsson JU, Woo V, Colman P, Christiansen E, et al. Efficacy and safety of liraglutide added to insulin treatment in type 1 diabetes: the ADJUNCT ONE treat-to-target randomized trial. Diabetes Care. 2016;39(10):1702–10.
Garg SK, Moser EG, Bode BW, Klaff LJ, Hiatt WR, Beatson C, et al. Effect of sitagliptin on post-prandial glucagon and GLP-1 levels in patients with type 1 diabetes: investigator-initiated, double-blind, randomized, placebo-controlled trial. Endocrine Pract. 2013;19(1):19–28.
Buse JB, Garg SK, Rosenstock J, Bailey TS, Banks P, Bode BW, et al. Sotagliflozin in in combination with optimized insulin therapy in adults with type 1 diabetes: the north American inTandem1 study. Diabetes Care. 2018;41(9):1970–80.
Dandona P, Mathieu C, Phillip M, Hansen L, Griffen SC, Tschope D, et al. Efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes (DEPICT-1): 24 week results from a multicentre, double-blind, phase 3, randomised controlled trial. Lancet Diab Endocrinol. 2017;5(11):864–76.
Danne T, Cariou B, Banks P, Brandle M, Brath H, Franek E, et al. HbA1c and hypoglycemia reductions at 24 and 52 weeks with sotagliflozin in combination with insulin in adults with type 1 diabetes: the European inTandem2 study. Diabetes Care. 2018;41(9):1981–90.
Famulla S, Pieber TR, Eilbracht J, Neubacher D, Soleymanlou N, Woerle HJ, et al. Glucose exposure and variability with empagliflozin as adjunct to insulin in patients with type 1 diabetes: continuous glucose monitoring data from a 4-week, randomized, placebo-controlled trial (EASE-1). Diabetes Technol Ther. 2017;19(1):49–60.
Pieber TR, Famulla S, Eilbracht J, Cescutti J, Soleymanlou N, Johansen OE, et al. Empagliflozin as adjunct to insulin in patients with type 1 diabetes: a 4-week, randomized, placebo-controlled trial (EASE-1). Diabetes Obes Metab. 2015;17(10):928–35.
Garg SK, Henry RR, Banks P, Buse JB, Davies MJ, Fulcher GR, et al. Effects of sotagliflozin added to insulin in patients with type 1 diabetes. N Engl J Med. 2017;377(24):2337–48.
Henry RR, Thakkar P, Tong C, Polidori D, Alba M. Efficacy and safety of canagliflozin, a sodium-glucose cotransporter 2 inhibitor, as add-on to insulin in patients with type 1 diabetes. Diabetes Care. 2015;38(12):2258–65.
Rodbard HW, Peters AL, Slee A, Cao A, Traina SB, Alba M. The effect of canagliflozin, a sodium glucose cotransporter 2 inhibitor, on glycemic end points assessed by continuous glucose monitoring and patient-reported outcomes among people with type 1 diabetes. Diabetes Care. 2017;40(2):171–80.
Peters AL, Henry RR, Thakkar P, Tong C, Alba M. Diabetic ketoacidosis with canagliflozin, a sodium-glucose cotransporter 2 inhibitor, in patients with type 1 diabetes. Diabetes Care. 2016;39(4):532–8.
Kuhadiya ND, Ghanim H, Mehta A, Garg M, Khan S, Hejna J, et al. Dapagliflozin as additional treatment to liraglutide and insulin in patients with type 1 diabetes. J Clin Endocrinol Metab. 2016;101(9):3506–15.
Sands AT, Zambrowicz BP, Rosenstock J, Lapuerta P, Bode BW, Garg SK, et al. Sotagliflozin, a dual SGLT1 and SGLT2 inhibitor, as adjunct therapy to insulin in type 1 diabetes. Diabetes Care. 2015;38(7):1181–8.
Shimada A, Hanafusa T, Yasui A, Lee G, Taneda Y, Sarashina A, et al. Empagliflozin as adjunct to insulin in Japanese participants with type 1 diabetes: results of a 4-week, double-blind, randomized, placebo-controlled phase 2 trial. Diabetes Obes Metab. 2018;20(9):2190–9.
Mathieu C, Dandona P, Gillard P, Senior P, Hasslacher C, Araki E, et al. Efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes (the DEPICT-2 study): 24-week results from a randomized controlled trial. Diabetes Care. 2018;41(9):1938–46.
Rosenstock J, Marquard J, Laffel LM, Neubacher D, Kaspers S, Cherney DZ, et al. Empagliflozin as adjunctive to insulin therapy in type 1 diabetes: the EASE trials. Diabetes Care. 2018;41(12):2560–9.
Edelman S, Garg S, Frias J, Maggs D, Wang Y, Zhang B, et al. A double-blind, placebo-controlled trial assessing pramlintide treatment in the setting of intensive insulin therapy in type 1 diabetes. Diabetes Care. 2006;29(10):2189–95.
Marrero DG, Crean J, Zhang B, Kellmeyer T, Gloster M, Herrmann K, et al. Effect of adjunctive pramlintide treatment on treatment satisfaction in patients with type 1 diabetes. Diabetes Care. 2007;30(2):210–6.
Kovatchev BP, Crean J, McCall A. Pramlintide reduces the risks associated with glucose variability in type 1 diabetes. Diabetes Technol Ther. 2008;10(5):391–6.
Herrmann K, Frias JP, Edelman SV, Lutz K, Shan K, Chen S, et al. Pramlintide improved measures of glycemic control and body weight in patients with type 1 diabetes mellitus undergoing continuous subcutaneous insulin infusion therapy. Postgrad Med. 2013;125(3):136–44.
Ratner RE, Dickey R, Fineman M, Maggs DG, Shen L, Strobel SA, et al. Amylin replacement with pramlintide as an adjunct to insulin therapy improves long-term glycaemic and weight control in type 1 diabetes mellitus: a 1-year, randomized controlled trial. Diab Med. 2004;21(11):1204–12.
Ratner R, Whitehouse F, Fineman MS, Strobel S, Shen L, Maggs DG, et al. Adjunctive therapy with pramlintide lowers HbA1c without concomitant weight gain and increased risk of severe hypoglycemia in patients with type 1 diabetes approaching glycemic targets. Exp Clin Endocrinol Diab. 2005;113(4):199–204.
Whitehouse F, Kruger DF, Fineman M, Shen L, Ruggles JA, Maggs DG, et al. A randomized study and open-label extension evaluating the long-term efficacy of pramlintide as an adjunct to insulin therapy in type 1 diabetes. Diabetes Care. 2002;25(4):724–30.
Madsbad S, Schmitz O, Ranstam J, Jakobsen G, Matthews DR. Improved glycemic control with no weight increase in patients with type 2 diabetes after once-daily treatment with the long-acting glucagon-like peptide 1 analog liraglutide (NN2211): a 12-week, double-blind, randomized, controlled trial. Diabetes Care. 2004;27(6):1335–42.
Scott R, Wu M, Sanchez M, Stein P. Efficacy and tolerability of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy over 12 weeks in patients with type 2 diabetes. Int J Clin Pract. 2007;61(1):171–80.
Goldberg RB, Holvey SM, Schneider J. A dose-response study of glimepiride in patients with NIDDM who have previously received sulfonylurea agents. The Glimepiride Protocol #201 Study Group. Diabetes Care. 1996;19(8):849–56.
Rosenstock J, Samols E, Muchmore DB, Schneider J. Glimepiride, a new once-daily sulfonylurea. A double-blind placebo-controlled study of NIDDM patients. Glimepiride Study Group. Diabetes Care. 1996;19(11):1194–9.
Simonson DC, Kourides IA, Feinglos M, Shamoon H, Fischette CT. Efficacy, safety, and dose-response characteristics of glipizide gastrointestinal therapeutic system on glycemic control and insulin secretion in NIDDM. Results of two multicenter, randomized, placebo-controlled clinical trials. The Glipizide Gastrointestinal Therapeutic System Study Group. Diabetes Care. 1997;20(4):597–606.
Fischer S, Patzak A, Rietzsch H, Schwanebeck U, Kohler C, Wildbrett J, et al. Influence of treatment with acarbose or glibenclamide on insulin sensitivity in type 2 diabetic patients. Diabetes Obes Metab. 2003;5(1):38–44.
Hanefeld M, Haffner SM, Menschikowski M, Koehler C, Temelkova-Kurktschiev T, Wildbrett J, et al. Different effects of acarbose and glibenclamide on proinsulin and insulin profiles in people with type 2 diabetes. Diabetes Res Clin Pract. 2002;55(3):221–7.
Hoffmann J, Spengler M. Efficacy of 24-week monotherapy with acarbose, glibenclamide, or placebo in NIDDM patients. The Essen Study. Diabetes Care. 1994;17(6):561–6.
Segal P, Feig PU, Schernthaner G, Ratzmann KP, Rybka J, Petzinna D, et al. The efficacy and safety of miglitol therapy compared with glibenclamide in patients with NIDDM inadequately controlled by diet alone. Diabetes Care. 1997;20(5):687–91.
Ebeling P, Teppo AM, Koistinen HA, Koivisto VA. Concentration of the complement activation product, acylation-stimulating protein, is related to C-reactive protein in patients with type 2 diabetes. Metab Clin Exp. 2001;50(3):283–7.
Coniff RF, Shapiro JA, Seaton TB, Bray GA. Multicenter, placebo-controlled trial comparing acarbose (BAY g 5421) with placebo, tolbutamide, and tolbutamide-plus-acarbose in non-insulin-dependent diabetes mellitus. Am J Med. 1995;98(5):443–51.
Johnson AB, Webster JM, Sum CF, Heseltine L, Argyraki M, Cooper BG, et al. The impact of metformin therapy on hepatic glucose production and skeletal muscle glycogen synthase activity in overweight type II diabetic patients. Metab Clin Exp. 1993;42(9):1217–22.
Tessari P, Biolo G, Bruttomesso D, Inchiostro S, Panebianco G, Vedovato M, et al. Effects of metformin treatment on whole-body and splanchnic amino acid turnover in mild type 2 diabetes. J Clin Endocrinol Metab. 1994;79(6):1553–60.
List JF, Woo V, Morales E, Tang W, Fiedorek FT. Sodium-glucose cotransport inhibition with dapagliflozin in type 2 diabetes. Diabetes Care. 2009;32(4):650–7.
Fonseca VA, Ferrannini E, Wilding JP, Wilpshaar W, Dhanjal P, Ball G, et al. Active- and placebo-controlled dose-finding study to assess the efficacy, safety, and tolerability of multiple doses of ipragliflozin in patients with type 2 diabetes mellitus. J Diabetes Complicat. 2013;27(3):268–73.
Garber AJ, Duncan TG, Goodman AM, Mills DJ, Rohlf JL. Efficacy of metformin in type II diabetes: results of a double-blind, placebo-controlled, dose-response trial. Am J Med. 1997;103(6):491–7.
Natali A, Baldeweg S, Toschi E, Capaldo B, Barbaro D, Gastaldelli A, et al. Vascular effects of improving metabolic control with metformin or rosiglitazone in type 2 diabetes. Diabetes Care. 2004;27(6):1349–57.
Fujioka K, Brazg RL, Raz I, Bruce S, Joyal S, Swanink R, et al. Efficacy, dose-response relationship and safety of once-daily extended-release metformin (Glucophage XR) in type 2 diabetic patients with inadequate glycaemic control despite prior treatment with diet and exercise: results from two double-blind, placebo-controlled studies. Diabetes Obes Metab. 2005;7(1):28–39.
Hoffmann J, Spengler M. Efficacy of 24-week monotherapy with acarbose, metformin, or placebo in dietary-treated NIDDM patients: the Essen-II study. Am J Med. 1997;103(6):483–90.
Horton ES, Clinkingbeard C, Gatlin M, Foley J, Mallows S, Shen S. Nateglinide alone and in combination with metformin improves glycemic control by reducing mealtime glucose levels in type 2 diabetes. Diabetes Care. 2000;23(11):1660–5.
Goldstein BJ, Feinglos MN, Lunceford JK, Johnson J, Williams-Herman DE. Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and metformin on glycemic control in patients with type 2 diabetes. Diabetes Care. 2007;30(8):1979–87.
Haak T, Meinicke T, Jones R, Weber S, von Eynatten M, Woerle HJ. Initial combination of linagliptin and metformin improves glycaemic control in type 2 diabetes: a randomized, double-blind, placebo-controlled study. Diabetes Obes Metab. 2012;14(6):565–74.
Hallsten K, Virtanen KA, Lonnqvist F, Sipila H, Oksanen A, Viljanen T, et al. Rosiglitazone but not metformin enhances insulin- and exercise-stimulated skeletal muscle glucose uptake in patients with newly diagnosed type 2 diabetes. Diabetes. 2002;51(12):3479–85.
Viljanen AP, Virtanen KA, Jarvisalo MJ, Hallsten K, Parkkola R, Ronnemaa T, et al. Rosiglitazone treatment increases subcutaneous adipose tissue glucose uptake in parallel with perfusion in patients with type 2 diabetes: a double-blind, randomized study with metformin. J Clin Endocrinol Metab. 2005;90(12):6523–8.
DeFronzo RA, Goodman AM. Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus. Multicenter Metformin Study Group. N Engl J Med. 1995;333(9):541–9.
Dornan TL, Heller SR, Peck GM, Tattersall RB. Double-blind evaluation of efficacy and tolerability of metformin in NIDDM. Diabetes Care. 1991;14(4):342–4.
Chiasson JL, Naditch L. The synergistic effect of miglitol plus metformin combination therapy in the treatment of type 2 diabetes. Diabetes Care. 2001;24(6):989–94.
Wagner H, Degerblad M, Thorell A, Nygren J, Stahle A, Kuhl J, et al. Combined treatment with exercise training and acarbose improves metabolic control and cardiovascular risk factor profile in subjects with mild type 2 diabetes. Diabetes Care. 2006;29(7):1471–7.
Coniff RF, Shapiro JA, Robbins D, Kleinfield R, Seaton TB, Beisswenger P, et al. Reduction of glycosylated hemoglobin and postprandial hyperglycemia by acarbose in patients with NIDDM. A placebo-controlled dose-comparison study. Diabetes Care. 1995;18(6):817–24.
Calle-Pascual A, Garcia-Honduvilla J, Martin-Alvarez PJ, Calle JR, Maranes JP. Influence of 16-week monotherapy with acarbose on cardiovascular risk factors in obese subjects with non-insulin-dependent diabetes mellitus: a controlled, double-blind comparison study with placebo. Diabetes Metab. 1996;22(3):201–2.
Scott R, Lintott CJ, Zimmet P, Campbell L, Bowen K, Welborn T. Will acarbose improve the metabolic abnormalities of insulin-resistant type 2 diabetes mellitus? Diabetes Res Clin Pract. 1999;43(3):179–85.
Delgado H, Lehmann T, Bobbioni-Harsch E, Ybarra J, Golay A. Acarbose improves indirectly both insulin resistance and secretion in obese type 2 diabetic patients. Diabetes Metab. 2002;28(3):195–200.
Hanefeld M, Schaper F, Koehler C, Bergmann S, Ugocsai P, Stelzer J, et al. Effect of acarbose on postmeal mononuclear blood cell response in patients with early type 2 diabetes: the AI(I) DA study. Horm Metab Res. 2009;41(2):132–6.
Rosenbaum P, Peres RB, Zanella MT, Ferreira SR. Improved glycemic control by acarbose therapy in hypertensive diabetic patients: effects on blood pressure and hormonal parameters. Braz J Med Biolo Res. 2002;35(8):877–84.
Hotta N, Kakuta H, Sano T, Matsumae H, Yamada H, Kitazawa S, et al. Long-term effect of acarbose on glycaemic control in non-insulin-dependent diabetes mellitus: a placebo-controlled double-blind study. Diab Med. 1993;10(2):134–8.
Chan JC, Chan KW, Ho LL, Fuh MM, Horn LC, Sheaves R, et al. An Asian multicenter clinical trial to assess the efficacy and tolerability of acarbose compared with placebo in type 2 diabetic patients previously treated with diet. Asian Acarbose Study Group. Diabetes Care. 1998;21(7):1058–61.
Gentile S, Turco S, Guarino G, Oliviero B, Annunziata S, Cozzolino D, et al. Effect of treatment with acarbose and insulin in patients with non-insulin-dependent diabetes mellitus associated with non-alcoholic liver cirrhosis. Diabetes Obes Metab. 2001;3(1):33–40.
Coniff RF, Shapiro JA, Seaton TB. Long-term efficacy and safety of acarbose in the treatment of obese subjects with non-insulin-dependent diabetes mellitus. Arch Intern Med. 1994;154(21):2442–8.
Chiasson JL, Josse RG, Hunt JA, Palmason C, Rodger NW, Ross SA, et al. The efficacy of acarbose in the treatment of patients with non-insulin-dependent diabetes mellitus. A multicenter controlled clinical trial. Ann Intern Med. 1994;121(12):928–35.
Meneilly GS, Ryan EA, Radziuk J, Lau DC, Yale JF, Morais J, et al. Effect of acarbose on insulin sensitivity in elderly patients with diabetes. Diabetes Care. 2000;23(8):1162–7.
Josse RG, Chiasson JL, Ryan EA, Lau DC, Ross SA, Yale JF, et al. Acarbose in the treatment of elderly patients with type 2 diabetes. Diabetes Res Clin Pract. 2003;59(1):37–42.
Hasche H, Mertes G, Bruns C, Englert R, Genthner P, Heim D, et al. Effects of acarbose treatment in type 2 diabetic patients under dietary training: a multicentre, double-blind, placebo-controlled, 2-year study. Diab Nutr Metab. 1999;12(4):277–85.
Iwamoto Y, Kosaka K, Kuzuya T, Akanuma Y, Shigeta Y, Kaneko T. Effects of troglitazone: a new hypoglycemic agent in patients with NIDDM poorly controlled by diet therapy. Diabetes Care. 1996;19(2):151–6.
Kumar S, Boulton AJ, Beck-Nielsen H, Berthezene F, Muggeo M, Persson B, et al. Troglitazone, an insulin action enhancer, improves metabolic control in NIDDM patients. Troglitazone Study Group. Diabetologia. 1996;39(6):701–9.
Patel J, Anderson RJ, Rappaport EB. Rosiglitazone monotherapy improves glycaemic control in patients with type 2 diabetes: a twelve-week, randomized, placebo-controlled study. Diabetes Obes Metab. 1999;1(3):165–72.
Raskin P, Rappaport EB, Cole ST, Yan Y, Patwardhan R, Freed MI. Rosiglitazone short-term monotherapy lowers fasting and post-prandial glucose in patients with type II diabetes. Diabetologia. 2000;43(3):278–84.
Miyazaki Y, Glass L, Triplitt C, Matsuda M, Cusi K, Mahankali A, et al. Effect of rosiglitazone on glucose and non-esterified fatty acid metabolism in type II diabetic patients. Diabetologia. 2001;44(12):2210–9.
Juhl CB, Hollingdal M, Porksen N, Prange A, Lonnqvist F, Schmitz O. Influence of rosiglitazone treatment on beta-cell function in type 2 diabetes: evidence of an increased ability of glucose to entrain high-frequency insulin pulsatility. J Clin Endocrinol Metab. 2003;88(8):3794–800.
Wallace TM, Levy JC, Matthews DR. An increase in insulin sensitivity and basal beta-cell function in diabetic subjects treated with pioglitazone in a placebo-controlled randomized study. Diab Med. 2004;21(6):568–76.
Gastaldelli A, Miyazaki Y, Pettiti M, Santini E, Ciociaro D, Defronzo RA, et al. The effect of rosiglitazone on the liver: decreased gluconeogenesis in patients with type 2 diabetes. J Clin Endocrinol Metab. 2006;91(3):806–12.
Sourij H, Zweiker R, Wascher TC. Effects of pioglitazone on endothelial function, insulin sensitivity, and glucose control in subjects with coronary artery disease and new-onset type 2 diabetes. Diabetes Care. 2006;29(5):1039–45.
Oz O, Tuncel E, Eryilmaz S, Fazlioglu M, Gul CB, Ersoy C, et al. Arterial elasticity and plasma levels of adiponectin and leptin in type 2 diabetic patients treated with thiazolidinediones. Endocrine. 2008;33(1):101–5.
Oz Gul O, Tuncel E, Yilmaz Y, Ulukaya E, Gul CB, Kiyici S, et al. Comparative effects of pioglitazone and rosiglitazone on plasma levels of soluble receptor for advanced glycation end products in type 2 diabetes mellitus patients. Metab Clin Exp. 2010;59(1):64–9.
Kong AP, Yamasaki A, Ozaki R, Saito H, Asami T, Ohwada S, et al. A randomized-controlled trial to investigate the effects of rivoglitazone, a novel PPAR gamma agonist on glucose-lipid control in type 2 diabetes. Diabetes Obes Metab. 2011;13(9):806–13.
Colca JR, VanderLugt JT, Adams WJ, Shashlo A, McDonald WG, Liang J, et al. Clinical proof-of-concept study with MSDC-0160, a prototype mTOT-modulating insulin sensitizer. Clin Pharmacol Ther. 2013;93(4):352–9.
Ebeling P, Teppo AM, Koistinen HA, Viikari J, Ronnemaa T, Nissen M, et al. Troglitazone reduces hyperglycaemia and selectively acute-phase serum proteins in patients with type II diabetes. Diabetologia. 1999;42(12):1433–8.
Miyazaki Y, Mahankali A, Matsuda M, Glass L, Mahankali S, Ferrannini E, et al. Improved glycemic control and enhanced insulin sensitivity in type 2 diabetic subjects treated with pioglitazone. Diabetes Care. 2001;24(4):710–9.
Phillips LS, Grunberger G, Miller E, Patwardhan R, Rappaport EB, Salzman A. Once- and twice-daily dosing with rosiglitazone improves glycemic control in patients with type 2 diabetes. Diabetes Care. 2001;24(2):308–15.
Rosenblatt S, Miskin B, Glazer NB, Prince MJ, Robertson KE. The impact of pioglitazone on glycemic control and atherogenic dyslipidemia in patients with type 2 diabetes mellitus. Coron Artery Dis. 2001;12(5):413–23.
Carey DG, Cowin GJ, Galloway GJ, Jones NP, Richards JC, Biswas N, et al. Effect of rosiglitazone on insulin sensitivity and body composition in type 2 diabetic patients [corrected]. Obes Res. 2002;10(10):1008–15.
Rosenstock J, Shen SG, Gatlin MR, Foley JE. Combination therapy with nateglinide and a thiazolidinedione improves glycemic control in type 2 diabetes. Diabetes Care. 2002;25(9):1529–33.
Lautamaki R, Airaksinen KE, Seppanen M, Toikka J, Luotolahti M, Ball E, et al. Rosiglitazone improves myocardial glucose uptake in patients with type 2 diabetes and coronary artery disease: a 16-week randomized, double-blind, placebo-controlled study. Diabetes. 2005;54(9):2787–94.
Gastaldelli A, Ferrannini E, Miyazaki Y, Matsuda M, Mari A, DeFronzo RA. Thiazolidinediones improve beta-cell function in type 2 diabetic patients. Am J Physiol Endocrinol Metab. 2007;292(3):E871–83.
Tan GD, Fielding BA, Currie JM, Humphreys SM, Desage M, Frayn KN, et al. The effects of rosiglitazone on fatty acid and triglyceride metabolism in type 2 diabetes. Diabetologia. 2005;48(1):83–95.
Miyazaki Y, Matsuda M, DeFronzo RA. Dose-response effect of pioglitazone on insulin sensitivity and insulin secretion in type 2 diabetes. Diabetes Care. 2002;25(3):517–23.
Fonseca VA, Valiquett TR, Huang SM, Ghazzi MN, Whitcomb RW. Troglitazone monotherapy improves glycemic control in patients with type 2 diabetes mellitus: a randomized, controlled study. The Troglitazone Study Group. J Clin Endocrinol Metab. 1998;83(9):3169–76.
Fonseca VA, Reynolds T, Hemphill D, Randolph C, Wall J, Valiquet TR, et al. Effect of troglitazone on fibrinolysis and activated coagulation in patients with non-insulin-dependent diabetes mellitus. J Diabetes Complicat. 1998;12(4):181–6.
Aronoff S, Rosenblatt S, Braithwaite S, Egan JW, Mathisen AL, Schneider RL. Pioglitazone hydrochloride monotherapy improves glycemic control in the treatment of patients with type 2 diabetes: a 6-month randomized placebo-controlled dose-response study. The Pioglitazone 001 Study Group. Diabetes Care. 2000;23(11):1605–11.
Haffner SM, Greenberg AS, Weston WM, Chen H, Williams K, Freed MI. Effect of rosiglitazone treatment on nontraditional markers of cardiovascular disease in patients with type 2 diabetes mellitus. Circulation. 2002;106(6):679–84.
Scherbaum WA, Goke B. Metabolic efficacy and safety of once-daily pioglitazone monotherapy in patients with type 2 diabetes: a double-blind, placebo-controlled study. Horm Metab Res. 2002;34(10):589–95.
Khan M, Murray FT, Karunaratne M, Perez A. Pioglitazone and reductions in post-challenge glucose levels in patients with type 2 diabetes. Diabetes Obes Metab. 2006;8(1):31–8.
Truitt KE, Goldberg RB, Rosenstock J, Chou HS, Merante D, Triscari J, et al. A 26-week, placebo- and pioglitazone-controlled, dose-ranging study of rivoglitazone, a novel thiazolidinedione for the treatment of type 2 diabetes. Curr Med Res Opin. 2010;26(6):1321–31.
Chou HS, Truitt KE, Moberly JB, Merante D, Choi Y, Mun Y, et al. A 26-week, placebo- and pioglitazone-controlled monotherapy study of rivoglitazone in subjects with type 2 diabetes mellitus. Diabetes Obes Metab. 2012;14(11):1000–9.
Ristic S, Byiers S, Foley J, Holmes D. Improved glycaemic control with dipeptidyl peptidase-4 inhibition in patients with type 2 diabetes: vildagliptin (LAF237) dose response. Diabetes Obes Metab. 2005;7(6):692–8.
Hanefeld M, Herman GA, Wu M, Mickel C, Sanchez M, Stein PP. Once-daily sitagliptin, a dipeptidyl peptidase-4 inhibitor, for the treatment of patients with type 2 diabetes. Curr Med Res Opin. 2007;23(6):1329–39.
Nonaka K, Kakikawa T, Sato A, Okuyama K, Fujimoto G, Kato N, et al. Efficacy and safety of sitagliptin monotherapy in Japanese patients with type 2 diabetes. Diabetes Res Clin Pract. 2008;79(2):291–8.
Rosenstock J, Sankoh S, List JF. Glucose-lowering activity of the dipeptidyl peptidase-4 inhibitor saxagliptin in drug-naive patients with type 2 diabetes. Diabetes Obes Metab. 2008;10(5):376–86.
Kikuchi M, Abe N, Kato M, Terao S, Mimori N, Tachibana H. Vildagliptin dose-dependently improves glycemic control in Japanese patients with type 2 diabetes mellitus. Diabetes Res Clin Pract. 2009;83(2):233–40.
Iwamoto Y, Taniguchi T, Nonaka K, Okamoto T, Okuyama K, Arjona Ferreira JC, et al. Dose-ranging efficacy of sitagliptin, a dipeptidyl peptidase-4 inhibitor, in Japanese patients with type 2 diabetes mellitus. Endocr J. 2010;57(5):383–94.
Pattzi HM, Pitale S, Alpizar M, Bennett C, O'Farrell AM, Li J, et al. Dutogliptin, a selective DPP4 inhibitor, improves glycaemic control in patients with type 2 diabetes: a 12-week, double-blind, randomized, placebo-controlled, multicentre trial. Diabetes Obes Metab. 2010;12(4):348–55.
Rhee EJ, Lee WY, Yoon KH, Yoo SJ, Lee IK, Baik SH, et al. A multicenter, randomized, placebo-controlled, double-blind phase II trial evaluating the optimal dose, efficacy and safety of LC 15-0444 in patients with type 2 diabetes. Diabetes Obes Metab. 2010;12(12):1113–9.
Seino Y, Fujita T, Hiroi S, Hirayama M, Kaku K. Efficacy and safety of alogliptin in Japanese patients with type 2 diabetes mellitus: a randomized, double-blind, dose-ranging comparison with placebo, followed by a long-term extension study. Curr Med Res Opin. 2011;27(9):1781–92.
Kawamori R, Inagaki N, Araki E, Watada H, Hayashi N, Horie Y, et al. Linagliptin monotherapy provides superior glycaemic control versus placebo or voglibose with comparable safety in Japanese patients with type 2 diabetes: a randomized, placebo and active comparator-controlled, double-blind study. Diabetes Obes Metab. 2012;14(4):348–57.
Kadowaki T, Kondo K. Efficacy, safety and dose-response relationship of teneligliptin, a dipeptidyl peptidase-4 inhibitor, in Japanese patients with type 2 diabetes mellitus. Diabetes Obes Metab. 2013;15(9):810–8.
Inagaki N, Onouchi H, Sano H, Funao N, Kuroda S, Kaku K. SYR-472, a novel once-weekly dipeptidyl peptidase-4 (DPP-4) inhibitor, in type 2 diabetes mellitus: a phase 2, randomised, double-blind, placebo-controlled trial. Lancet Diab Endocrinol. 2014;2(2):125–32.
Sheu WH, Gantz I, Chen M, Suryawanshi S, Mirza A, Goldstein BJ, et al. Safety and efficacy of omarigliptin (MK-3102), a novel once-weekly DPP-4 inhibitor for the treatment of patients with type 2 diabetes. Diabetes Care. 2015;38(11):2106–14.
Yoon SA, Han BG, Kim SG, Han SY, Jo YI, Jeong KH, et al. Efficacy, safety and albuminuria-reducing effect of gemigliptin in Korean type 2 diabetes patients with moderate to severe renal impairment: a 12-week, double-blind randomized study (the GUARD study). Diabetes Obes Metab. 2017;19(4):590–8.
Pan C, Han P, Ji Q, Li C, Lu J, Yang J, et al. Efficacy and safety of alogliptin in patients with type 2 diabetes mellitus: a multicentre randomized double-blind placebo-controlled phase 3 study in mainland China, Taiwan, and Hong Kong. J Diab. 2017;9(4):386–95.
Agarwal P, Jindal C, Sapakal V. Efficacy and safety of teneligliptin in Indian patients with inadequately controlled type 2 diabetes mellitus: a randomized, double-blind study. Indian J Endocrinol Metab. 2018;22(1):41–6.
Raz I, Hanefeld M, Xu L, Caria C, Williams-Herman D, Khatami H. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy in patients with type 2 diabetes mellitus. Diabetologia. 2006;49(11):2564–71.
Mohan V, Yang W, Son HY, Xu L, Noble L, Langdon RB, et al. Efficacy and safety of sitagliptin in the treatment of patients with type 2 diabetes in China, India, and Korea. Diabetes Res Clin Pract. 2009;83(1):106–16.
Aschner P, Kipnes MS, Lunceford JK, Sanchez M, Mickel C, Williams-Herman DE. Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycemic control in patients with type 2 diabetes. Diabetes Care. 2006;29(12):2632–7.
Dejager S, Razac S, Foley JE, Schweizer A. Vildagliptin in drug-naive patients with type 2 diabetes: a 24-week, double-blind, randomized, placebo-controlled, multiple-dose study. Horm Met Res. 2007;39(3):218–23.
Pi-Sunyer FX, Schweizer A, Mills D, Dejager S. Efficacy and tolerability of vildagliptin monotherapy in drug-naive patients with type 2 diabetes. Diabetes Res Clin Pract. 2007;76(1):132–8.
Rosenstock J, Aguilar-Salinas C, Klein E, Nepal S, List J, Chen R. Effect of saxagliptin monotherapy in treatment-naive patients with type 2 diabetes. Curr Med Res Opin. 2009;25(10):2401–11.
Del Prato S, Barnett AH, Huisman H, Neubacher D, Woerle HJ, Dugi KA. Effect of linagliptin monotherapy on glycaemic control and markers of beta-cell function in patients with inadequately controlled type 2 diabetes: a randomized controlled trial. Diabetes Obes Metab. 2011;13(3):258–67.
Pan CY, Yang W, Tou C, Gause-Nilsson I, Zhao J. Efficacy and safety of saxagliptin in drug-naive Asian patients with type 2 diabetes mellitus: a randomized controlled trial. Diabetes Metab Res Rev. 2012;28(3):268–75.
Frederich R, McNeill R, Berglind N, Fleming D, Chen R. The efficacy and safety of the dipeptidyl peptidase-4 inhibitor saxagliptin in treatment-naive patients with type 2 diabetes mellitus: a randomized controlled trial. Diabetol Metab Syndr. 2012;4(1):36.
Yang SJ, Min KW, Gupta SK, Park JY, Shivane VK, Pitale SU, et al. A multicentre, multinational, randomized, placebo-controlled, double-blind, phase 3 trial to evaluate the efficacy and safety of gemigliptin (LC15-0444) in patients with type 2 diabetes. Diabetes Obes Metab. 2013;15(5):410–6.
Roden M, Weng J, Eilbracht J, Delafont B, Kim G, Woerle HJ, et al. Empagliflozin monotherapy with sitagliptin as an active comparator in patients with type 2 diabetes: a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Diab Endocrinol. 2013;1(3):208–19.
Inagaki N, Onouchi H, Maezawa H, Kuroda S, Kaku K. Once-weekly trelagliptin versus daily alogliptin in Japanese patients with type 2 diabetes: a randomised, double-blind, phase 3, non-inferiority study. Lancet Diab Endocrinol. 2015;3(3):191–7.
Wu W, Li Y, Chen X, Lin D, Xiang S, Shen F, et al. Effect of Linagliptin on glycemic control in Chinese patients with newly-diagnosed, drug-naive type 2 diabetes mellitus: a randomized controlled trial. Med Sci Monit. 2015;21:2678–84.
Hong S, Park CY, Han KA, Chung CH, Ku BJ, Jang HC, et al. Efficacy and safety of teneligliptin, a novel dipeptidyl peptidase-4 inhibitor, in Korean patients with type 2 diabetes mellitus: a 24-week multicentre, randomized, double-blind, placebo-controlled phase III trial. Diabetes Obes Metab. 2016;18(5):528–32.
Ji L, Han P, Wang X, Liu J, Zheng S, Jou YM, et al. Randomized clinical trial of the safety and efficacy of sitagliptin and metformin co-administered to Chinese patients with type 2 diabetes mellitus. J Diab Invest. 2016;7(5):727–36.
Chacra A, Gantz I, Mendizabal G, Durlach L, O'Neill EA, Zimmer Z, et al. A randomised, double-blind, trial of the safety and efficacy of omarigliptin (a once-weekly DPP-4 inhibitor) in subjects with type 2 diabetes and renal impairment. Int J Clin Pract. 2017;71(6):e12955.
Home P, Ravi Shankar R, Gantz I, Iredale C, O'Neill EA, Jain L, et al. A randomized, double-blind trial evaluating the efficacy and safety of monotherapy with the once-weekly dipeptidyl peptidase-4 inhibitor omarigliptin in people with type 2 diabetes. Diabetes Res Clin Pract. 2018;138:253–61.
Gantz I, Okamoto T, Ito Y, Okuyama K, O'Neill EA, Kaufman KD, et al. A randomized, placebo- and sitagliptin-controlled trial of the safety and efficacy of omarigliptin, a once-weekly dipeptidyl peptidase-4 inhibitor, in Japanese patients with type 2 diabetes. Diabetes Obes Metab. 2017;19(11):1602–9.
Pratley RE, Fleck P, Wilson C. Efficacy and safety of initial combination therapy with alogliptin plus metformin versus either as monotherapy in drug-naive patients with type 2 diabetes: a randomized, double-blind, 6-month study. Diabetes Obes Metab. 2014;16(7):613–21.
Ji L, Li L, Kuang J, Yang T, Kim DJ, Kadir AA, et al. Efficacy and safety of fixed-dose combination therapy, alogliptin plus metformin, in Asian patients with type 2 diabetes: a phase 3 trial. Diabetes Obes Metab. 2017;19(5):754–8.
Scherbaum WA, Schweizer A, Mari A, Nilsson PM, Lalanne G, Jauffret S, et al. Efficacy and tolerability of vildagliptin in drug-naive patients with type 2 diabetes and mild hyperglycaemia*. Diabetes Obes Metab. 2008;10(8):675–82.
Ott C, Jumar A, Striepe K, Friedrich S, Karg MV, Bramlage P, et al. A randomised study of the impact of the SGLT2 inhibitor dapagliflozin on microvascular and macrovascular circulation. Cardiovasc Diabetol. 2017;16(1):26.
Ferrannini E, Seman L, Seewaldt-Becker E, Hantel S, Pinnetti S, Woerle HJ. A phase IIb, randomized, placebo-controlled study of the SGLT2 inhibitor empagliflozin in patients with type 2 diabetes. Diabetes Obes Metab. 2013;15(8):721–8.
Inagaki N, Kondo K, Yoshinari T, Maruyama N, Susuta Y, Kuki H. Efficacy and safety of canagliflozin in Japanese patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, 12-week study. Diabetes Obes Metab. 2013;15(12):1136–45.
Kaku K, Inoue S, Matsuoka O, Kiyosue A, Azuma H, Hayashi N, et al. Efficacy and safety of dapagliflozin as a monotherapy for type 2 diabetes mellitus in Japanese patients with inadequate glycaemic control: a phase II multicentre, randomized, double-blind, placebo-controlled trial. Diabetes Obes Metab. 2013;15(5):432–40.
Seino Y, Sasaki T, Fukatsu A, Sakai S, Samukawa Y. Efficacy and safety of luseogliflozin monotherapy in Japanese patients with type 2 diabetes mellitus: a 12-week, randomized, placebo-controlled, phase II study. Curr Med Res Opin. 2014;30(7):1219–30.
Seino Y, Sasaki T, Fukatsu A, Ubukata M, Sakai S, Samukawa Y. Dose-finding study of luseogliflozin in Japanese patients with type 2 diabetes mellitus: a 12-week, randomized, double-blind, placebo-controlled, phase II study. Curr Med Res Opin. 2014;30(7):1231–44.
Ikeda S, Takano Y, Cynshi O, Tanaka R, Christ AD, Boerlin V, et al. A novel and selective sodium-glucose cotransporter-2 inhibitor, tofogliflozin, improves glycaemic control and lowers body weight in patients with type 2 diabetes mellitus. Diabetes Obes Metab. 2015;17(10):984–93.
Sykes AP, Kemp GL, Dobbins R, O'Connor-Semmes R, Almond SR, Wilkison WO, et al. Randomized efficacy and safety trial of once-daily remogliflozin etabonate for the treatment of type 2 diabetes. Diabetes Obes Metab. 2015;17(1):98–101.
Sykes AP, O'Connor-Semmes R, Dobbins R, Dorey DJ, Lorimer JD, Walker S, et al. Randomized trial showing efficacy and safety of twice-daily remogliflozin etabonate for the treatment of type 2 diabetes. Diabetes Obes Metab. 2015;17(1):94–7.
Heerspink HJ, Johnsson E, Gause-Nilsson I, Cain VA, Sjostrom CD. Dapagliflozin reduces albuminuria in patients with diabetes and hypertension receiving renin-angiotensin blockers. Diabetes Obes Metab. 2016;18(6):590–7.
Ferrannini E, Ramos SJ, Salsali A, Tang W, List JF. Dapagliflozin monotherapy in type 2 diabetic patients with inadequate glycemic control by diet and exercise: a randomized, double-blind, placebo-controlled, phase 3 trial. Diabetes Care. 2010;33(10):2217–24.
Bailey CJ, Iqbal N, T'Joen C, List JF. Dapagliflozin monotherapy in drug-naive patients with diabetes: a randomized-controlled trial of low-dose range. Diabetes Obes Metab. 2012;14(10):951–9.
Inagaki N, Kondo K, Yoshinari T, Takahashi N, Susuta Y, Kuki H. Efficacy and safety of canagliflozin monotherapy in Japanese patients with type 2 diabetes inadequately controlled with diet and exercise: a 24-week, randomized, double-blind, placebo-controlled, phase III study. Expert Opin Pharmacother. 2014;15(11):1501–15.
Kaku K, Watada H, Iwamoto Y, Utsunomiya K, Terauchi Y, Tobe K, et al. Efficacy and safety of monotherapy with the novel sodium/glucose cotransporter-2 inhibitor tofogliflozin in Japanese patients with type 2 diabetes mellitus: a combined phase 2 and 3 randomized, placebo-controlled, double-blind, parallel-group comparative study. Cardiovasc Diabetol. 2014;13:65.
Ji L, Ma J, Li H, Mansfield TA, T’Joen CL, Iqbal N, et al. Dapagliflozin as monotherapy in drug-naive Asian patients with type 2 diabetes mellitus: a randomized, blinded, prospective phase III study. Clin Ther. 2014;36(1):84–100 e9.
Kashiwagi A, Takahashi H, Ishikawa H, Yoshida S, Kazuta K, Utsuno A, et al. A randomized, double-blind, placebo-controlled study on long-term efficacy and safety of ipragliflozin treatment in patients with type 2 diabetes mellitus and renal impairment: results of the long-term ASP1941 safety evaluation in patients with type 2 diabetes with renal impairment (LANTERN) study. Diabetes Obes Metab. 2015;17(2):152–60.
Kashiwagi A, Kazuta K, Goto K, Yoshida S, Ueyama E, Utsuno A. Ipragliflozin in combination with metformin for the treatment of Japanese patients with type 2 diabetes: ILLUMINATE, a randomized, double-blind, placebo-controlled study. Diabetes Obes Metab. 2015;17(3):304–8.
Seino Y, Sasaki T, Fukatsu A, Ubukata M, Sakai S, Samukawa Y. Efficacy and safety of luseogliflozin as monotherapy in Japanese patients with type 2 diabetes mellitus: a randomized, double-blind, placebo-controlled, phase 3 study. Curr Med Res Opin. 2014;30(7):1245–55.
Seino Y, Inagaki N, Haneda M, Kaku K, Sasaki T, Fukatsu A, et al. Efficacy and safety of luseogliflozin added to various oral antidiabetic drugs in Japanese patients with type 2 diabetes mellitus. J Diab Invest. 2015;6(4):443–53.
Haneda M, Seino Y, Inagaki N, Kaku K, Sasaki T, Fukatsu A, et al. Influence of renal function on the 52-week efficacy and safety of the sodium glucose cotransporter 2 inhibitor luseogliflozin in Japanese patients with type 2 diabetes mellitus. Clin Ther. 2016;38(1):66–88.e20.
Li FF, Gao G, Li Q, Zhu HH, Su XF, Wu JD, et al. Influence of dapagliflozin on glycemic variations in patients with newly diagnosed type 2 diabetes mellitus. J Diab Res. 2016;2016:5347262.
Pollock C, Stefánsson B, Reyner D, et al. Albuminuria-lowering effect of dapagliflozin alone and in combination with saxagliptin and effect of dapagliflozin and saxagliptin on glycaemic control in patients with type 2 diabetes and chronic kidney disease (DELIGHT): a randomised, double-blind, placebo-controlled trial. Lancet Diabetes Endocrinol. 2019;7(6):429–41.
Stenlof K, Cefalu WT, Kim KA, Alba M, Usiskin K, Tong C, et al. Efficacy and safety of canagliflozin monotherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet and exercise. Diabetes Obes Metab. 2013;15(4):372–82.
Terra SG, Focht K, Davies M, Frias J, Derosa G, Darekar A, et al. Phase III, efficacy and safety study of ertugliflozin monotherapy in people with type 2 diabetes mellitus inadequately controlled with diet and exercise alone. Diabetes Obes Metab. 2017;19(5):721–8.
Aronson R, Frias J, Goldman A, et al. Long-term efficacy and safety of ertugliflozin monotherapy in patients with inadequately controlled T2DM despite diet and exercise: VERTIS MONO extension study. Diab Obes Metab. 2018;20(6):1453.
Lins PE, Lundblad S, Persson-Trotzig E, Adamson U. Glibenclamide improves the response to insulin treatment in non-insulin-dependent diabetics with second failure to sulfonylurea therapy. Acta Med Scand. 1988;223(2):171–9.
Stuart CA, Gilkison CR, Carlson RF, Stuart CA, Gilkison CR, Carlson RF. Effect of adding a sulfonylurea in patients with non-insulin-dependent diabetes mellitus previously well controlled with insulin. Endocrine Pract. 1997;3(6):344–8.
Forst T, Uhlig-Laske B, Ring A, Graefe-Mody U, Friedrich C, Herbach K, et al. Linagliptin (BI 1356), a potent and selective DPP-4 inhibitor, is safe and efficacious in combination with metformin in patients with inadequately controlled type 2 diabetes. Diab Med. 2010;27(12):1409–19.
Burant CF, Viswanathan P, Marcinak J, Cao C, Vakilynejad M, Xie B, et al. TAK-875 versus placebo or glimepiride in type 2 diabetes mellitus: a phase 2, randomised, double-blind, placebo-controlled trial. Lancet. 2012;379(9824):1403–11.
Schade DS, Mitchell WJ, Griego G. Addition of sulfonylurea to insulin treatment in poorly controlled type II diabetes. A double-blind, randomized clinical trial. Jama. 1987;257(18):2441–5.
Stenman S, Groop PH, Saloranta C, Totterman KJ, Fyhrqvist F, Groop L. Effects of the combination of insulin and glibenclamide in type 2 (non-insulin-dependent) diabetic patients with secondary failure to oral hypoglycaemic agents. Diabetologia. 1988;31(4):206–13.
Riddle M, Hart J, Bingham P, Garrison C, McDaniel P. Combined therapy for obese type 2 diabetes: suppertime mixed insulin with daytime sulfonylurea. Am J Med Sci. 1992;303(3):151–6.
Feinglos M, Dailey G, Cefalu W, Osei K, Tayek J, Canovatchel W, et al. Effect on glycemic control of the addition of 2.5 mg glipizide GITS to metformin in patients with T2DM. Diabetes Res Clin Pract. 2005;68(2):167–75.
Lewitt MS, Yu VK, Rennie GC, Carter JN, Marel GM, Yue DK, et al. Effects of combined insulin-sulfonylurea therapy in type II patients. Diabetes Care. 1989;12(6):379–83.
Riddle MC, Schneider J. Beginning insulin treatment of obese patients with evening 70/30 insulin plus glimepiride versus insulin alone. Glimepiride Combination Group. Diabetes Care. 1998;21(7):1052–7.
Roberts VL, Stewart J, Issa M, Lake B, Melis R. Triple therapy with glimepiride in patients with type 2 diabetes mellitus inadequately controlled by metformin and a thiazolidinedione: results of a 30-week, randomized, double-blind, placebo-controlled, parallel-group study. Clin Ther. 2005;27(10):1535–47.
Nauck M, Frid A, Hermansen K, Shah NS, Tankova T, Mitha IH, et al. Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study. Diabetes Care. 2009;32(1):84–90.
Karlander SG, Gutniak MK, Efendic S. Effects of combination therapy with glyburide and insulin on serum lipid levels in NIDDM patients with secondary sulfonylurea failure. Diabetes Care. 1991;14(11):963–7.
Camerini-Davalos RA, Bloodworth JM Jr, Velasco CA, Reddi AS. Effect of insulin-glipizide combination on skeletal muscle capillary basement membrane width in diabetic patients. Clin Ther. 1994;16(6):952–61.
Willms B, Ruge D. Comparison of acarbose and metformin in patients with type 2 diabetes mellitus insufficiently controlled with diet and sulphonylureas: a randomized, placebo-controlled study. Diabetic Med. 1999;16(9):755–61.
Aviles-Santa L, Sinding J, Raskin P. Effects of metformin in patients with poorly controlled, insulin-treated type 2 diabetes mellitus. A randomized, double-blind, placebo-controlled trial. Ann Intern Med. 1999;131(3):182–8.
Hermann LS, Kalen J, Katzman P, Lager I, Nilsson A, Norrhamn O, et al. Long-term glycaemic improvement after addition of metformin to insulin in insulin-treated obese type 2 diabetes patients. Diabetes Obes Metab. 2001;3(6):428–34.
Douek IF, Allen SE, Ewings P, Gale EA, Bingley PJ. Continuing metformin when starting insulin in patients with type 2 diabetes: a double-blind randomized placebo-controlled trial. Diabetic Med. 2005;22(5):634–40.
Gram J, Henriksen JE, Grodum E, Juhl H, Hansen TB, Christiansen C, et al. Pharmacological treatment of the pathogenetic defects in type 2 diabetes: the randomized multicenter South Danish Diabetes Study. Diabetes Care. 2011;34(1):27–33.
Kooy A, de Jager J, Lehert P, Bets D, Wulffele MG, Donker AJ, et al. Long-term effects of metformin on metabolism and microvascular and macrovascular disease in patients with type 2 diabetes mellitus. Arch Intern Med. 2009;169(6):616–25.
Nemoto M, Tajima N, Kawamori R. Efficacy of combined use of miglitol in type 2 diabetes patients receiving insulin therapy-placebo-controlled double-blind comparative study. Acta Diabetol. 2011;48(1):15–20.
Hwu CM, Ho LT, Fuh MM, Siu SC, Sutanegara D, Piliang S, et al. Acarbose improves glycemic control in insulin-treated Asian type 2 diabetic patients: results from a multinational, placebo-controlled study. Diabetes Res Clin Pract. 2003;60(2):111–8.
Schnell O, Mertes G, Standl E. Acarbose and metabolic control in patients with type 2 diabetes with newly initiated insulin therapy. Diabetes Obes Metab. 2007;9(6):853–8.
Kelley DE, Bidot P, Freedman Z, Haag B, Podlecki D, Rendell M, et al. Efficacy and safety of acarbose in insulin-treated patients with type 2 diabetes. Diabetes Care. 1998;21(12):2056–61.
Lam KS, Tiu SC, Tsang MW, Ip TP, Tam SC. Acarbose in NIDDM patients with poor control on conventional oral agents. A 24-week placebo-controlled study. Diabetes Care. 1998;21(7):1154–8.
Mitrakou A, Tountas N, Raptis AE, Bauer RJ, Schulz H, Raptis SA. Long-term effectiveness of a new alpha-glucosidase inhibitor (BAY m1099-miglitol) in insulin-treated type 2 diabetes mellitus. Diab Med. 1998;15(8):657–60.
Standl E, Baumgartl HJ, Fuchtenbusch M, Stemplinger J. Effect of acarbose on additional insulin therapy in type 2 diabetic patients with late failure of sulphonylurea therapy. Diabetes Obes Metab. 1999;1(4):215–20.
Standl E, Schernthaner G, Rybka J, Hanefeld M, Raptis SA, Naditch L. Improved glycaemic control with miglitol in inadequately-controlled type 2 diabetics. Diabetes Res Clin Pract. 2001;51(3):205–13.
Lin BJ, Wu HP, Huang HS, Juang JH, Sison A, Bin Abdul Kadir DK, et al. Efficacy and tolerability of acarbose in Asian patients with type 2 diabetes inadequately controlled with diet and sulfonylureas. J Diabetes Complicat. 2003;17(4):179–85.
Phillips P, Karrasch J, Scott R, Wilson D, Moses R. Acarbose improves glycemic control in overweight type 2 diabetic patients insufficiently treated with metformin. Diabetes Care. 2003;26(2):269–73.
Hsieh SH, Shih KC, Chou CW, Chu CH. Evaluation of the efficacy and tolerability of miglitol in Chinese patients with type 2 diabetes mellitus inadequately controlled by diet and sulfonylureas. Acta Diabetol. 2011;48(1):71–7.
Halimi S, Le Berre MA, Grange V. Efficacy and safety of acarbose add-on therapy in the treatment of overweight patients with type 2 diabetes inadequately controlled with metformin: a double-blind, placebo-controlled study. Diabetes Res Clin Pract. 2000;50(1):49–56.
Van Gaal L, Maislos M, Schernthaner G, Rybka J, Segal P. Miglitol combined with metformin improves glycaemic control in type 2 diabetes. Diabetes Obes Metab. 2001;3(5):326–31.
Johnston PS, Feig PU, Coniff RF, Krol A, Kelley DE, Mooradian AD. Chronic treatment of African-American type 2 diabetic patients with alpha-glucosidase inhibition. Diabetes Care. 1998;21(3):416–22.
Johnston PS, Feig PU, Coniff RF, Krol A, Davidson JA, Haffner SM. Long-term titrated-dose alpha-glucosidase inhibition in non-insulin-requiring Hispanic NIDDM patients. Diabetes Care. 1998;21(3):409–15.
Bachmann W, Petzinna D, Raptis SA, Wascher T, Westermeier T. Long-term improvement of metabolic control by acarbose in type 2 diabetes patients poorly controlled with maximum sulfonylurea therapy. Clin Drug Invest. 2003;23(10):679–86.
Iwamoto Y, Kosaka K, Kuzuya T, Akanuma Y, Shigeta Y, Kaneko T. Effect of combination therapy of troglitazone and sulphonylureas in patients with type 2 diabetes who were poorly controlled by sulphonylurea therapy alone. Diabetic Med. 1996;13(4):365–70.
Kawamori R, Matsuhisa M, Kinoshita J, Mochizuki K, Niwa M, Arisaka T, et al. Pioglitazone enhances splanchnic glucose uptake as well as peripheral glucose uptake in non-insulin-dependent diabetes mellitus. AD-4833 Clamp-OGL Study Group. Diabetes Res Clin Pract. 1998;41(1):35–43.
Kelly IE, Han TS, Walsh K, Lean ME. Effects of a thiazolidinedione compound on body fat and fat distribution of patients with type 2 diabetes. Diabetes Care. 1999;22(2):288–93.
Pan C, Gao Y, Gao X, Li G, Luo B, Shi H, et al. The efficacy and safety of pioglitazone hydrochloride in combination with sulphonylureas and metfomin in the treatment of type 2 diabetes mellitus a 12-week randomized multi-centres placebo-controlled parallel study. Zhonghua Nei Ke Za Zhi. 2002;41(6):388–92.
Buras J, Reenstra WR, Orlow D, Horton ES, Veves A. Troglitazone-induced changes in adiponectin do not affect endothelial function in diabetes. Obes Res. 2005;13(7):1167–74.
Mimura K, Umeda F, Hiramatsu S, Taniguchi S, Ono Y, Nakashima N, et al. Effects of a new oral hypoglycaemic agent (CS-045) on metabolic abnormalities and insulin resistance in type 2 diabetes. Diabetic Med. 1994;11(7):685–91.
Osende JI, Badimon JJ, Fuster V, Herson P, Rabito P, Vidhun R, et al. Blood thrombogenicity in type 2 diabetes mellitus patients is associated with glycemic control. J Am Coll Cardiol. 2001;38(5):1307–12.
Brackenridge AL, Jackson N, Jefferson W, Stolinski M, Shojaee-Moradie F, Hovorka R, et al. Effects of rosiglitazone and pioglitazone on lipoprotein metabolism in patients with type 2 diabetes and normal lipids. Diabetic Med. 2009;26(5):532–9.
Buysschaert M, Bobbioni E, Starkie M, Frith L. Troglitazone in combination with sulphonylurea improves glycaemic control in type 2 diabetic patients inadequately controlled by sulphonylurea therapy alone. Troglitazone Study Group. Diab Med. 1999;16(2):147–53.
Kipnes MS, Krosnick A, Rendell MS, Egan JW, Mathisen AL, Schneider RL. Pioglitazone hydrochloride in combination with sulfonylurea therapy improves glycemic control in patients with type 2 diabetes mellitus: a randomized, placebo-controlled study. Am J Med. 2001;111(1):10–7.
Scott R, Loeys T, Davies MJ, Engel SS. Efficacy and safety of sitagliptin when added to ongoing metformin therapy in patients with type 2 diabetes. Diabetes Obes Metab. 2008;10(10):959–69.
Berhanu P, Perez A, Yu S. Effect of pioglitazone in combination with insulin therapy on glycaemic control, insulin dose requirement and lipid profile in patients with type 2 diabetes previously poorly controlled with combination therapy. Diabetes Obes Metab. 2007;9(4):512–20.
Yale JF, Valiquett TR, Ghazzi MN, Owens-Grillo JK, Whitcomb RW, Foyt HL. The effect of a thiazolidinedione drug, troglitazone, on glycemia in patients with type 2 diabetes mellitus poorly controlled with sulfonylurea and metformin. A multicenter, randomized, double-blind, placebo-controlled trial. Ann Intern Med. 2001;134(9 Pt 1):737–45.
Zhu XX, Pan CY, Li GW, Shi HL, Tian H, Yang WY, et al. Addition of rosiglitazone to existing sulfonylurea treatment in chinese patients with type 2 diabetes and exposure to hepatitis B or C. Diabetes Technol Ther. 2003;5(1):33–42.
Dailey GE 3rd, Noor MA, Park JS, Bruce S, Fiedorek FT. Glycemic control with glyburide/metformin tablets in combination with rosiglitazone in patients with type 2 diabetes: a randomized, double-blind trial. Am J Med. 2004;116(4):223–9.
Smith SR, De Jonge L, Volaufova J, Li Y, Xie H, Bray GA. Effect of pioglitazone on body composition and energy expenditure: a randomized controlled trial. Metab Clin Exp. 2005;54(1):24–32.
Davidson JA, McMorn SO, Waterhouse BR, Cobitz AR. A 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study of the efficacy and tolerability of combination therapy with rosiglitazone and sulfonylurea in African American and Hispanic American patients with type 2 diabetes inadequately controlled with sulfonylurea monotherapy. Clin Ther. 2007;29(9):1900–14.
Hollander P, Yu D, Chou HS. Low-dose rosiglitazone in patients with insulin-requiring type 2 diabetes. Arch Intern Med. 2007;167(12):1284–90.
Sridhar S, Walia R, Sachdeva N, Bhansali A. Effect of pioglitazone on testosterone in eugonadal men with type 2 diabetes mellitus: a randomized double-blind placebo-controlled study. Clin Endocrinol. 2013;78(3):454–9.
Buse JB, Gumbiner B, Mathias NP, Nelson DM, Faja BW, Whitcomb RW. Troglitazone use in insulin-treated type 2 diabetic patients. The Troglitazone Insulin Study Group. Diabetes Care. 1998;21(9):1455–61.
Schwartz S, Raskin P, Fonseca V, Graveline JF. Effect of troglitazone in insulin-treated patients with type II diabetes mellitus. Troglitazone and Exogenous Insulin Study Group. N Engl J Med. 1998;338(13):861–6.
Fonseca V, Rosenstock J, Patwardhan R, Salzman A. Effect of metformin and rosiglitazone combination therapy in patients with type 2 diabetes mellitus: a randomized controlled trial. Jama. 2000;283(13):1695–702.
Wolffenbuttel BH, Gomis R, Squatrito S, Jones NP, Patwardhan RN. Addition of low-dose rosiglitazone to sulphonylurea therapy improves glycaemic control in type 2 diabetic patients. Diab Med. 2000;17(1):40–7.
Raskin P, Rendell M, Riddle MC, Dole JF, Freed MI, Rosenstock J. A randomized trial of rosiglitazone therapy in patients with inadequately controlled insulin-treated type 2 diabetes. Diabetes Care. 2001;24(7):1226–32.
Barnett AH, Grant PJ, Hitman GA, Mather H, Pawa M, Robertson L, et al. Rosiglitazone in type 2 diabetes mellitus: an evaluation in British Indo-Asian patients. Diab Med. 2003;20(5):387–93.
Rosenstock J, Chou HS, Matthaei S, Seidel DK, Hamann A. Potential benefits of early addition of rosiglitazone in combination with glimepiride in the treatment of type 2 diabetes. Diabetes Obes Metab. 2008;10(10):862–73.
Marre M, Shaw J, Brandle M, Bebakar WM, Kamaruddin NA, Strand J, et al. Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with type 2 diabetes (LEAD-1 SU). Diab Med. 2009;26(3):268–78.
Henriksen K, Byrjalsen I, Qvist P, Beck-Nielsen H, Hansen G, Riis BJ, et al. Efficacy and safety of the PPARgamma partial agonist balaglitazone compared with pioglitazone and placebo: a phase III, randomized, parallel-group study in patients with type 2 diabetes on stable insulin therapy. Diabetes Metab Res Rev. 2011;27(4):392–401.
Nakamura T, Ushiyama C, Osada S, Hara M, Shimada N, Koide H. Pioglitazone reduces urinary podocyte excretion in type 2 diabetes patients with microalbuminuria. Metab Clin Exp. 2001;50(10):1193–6.
Reynolds LR, Konz EC, Frederich RC, Anderson JW. Rosiglitazone amplifies the benefits of lifestyle intervention measures in long-standing type 2 diabetes mellitus. Diabetes Obes Metab. 2002;4(4):270–5.
Yang WS, Jeng CY, Wu TJ, Tanaka S, Funahashi T, Matsuzawa Y, et al. Synthetic peroxisome proliferator-activated receptor-gamma agonist, rosiglitazone, increases plasma levels of adiponectin in type 2 diabetic patients. Diabetes Care. 2002;25(2):376–80.
Mattoo V, Eckland D, Widel M, Duran S, Fajardo C, Strand J, et al. Metabolic effects of pioglitazone in combination with insulin in patients with type 2 diabetes mellitus whose disease is not adequately controlled with insulin therapy: results of a six-month, randomized, double-blind, prospective, multicenter, parallel-group study. Clin Ther. 2005;27(5):554–67.
Derosa G, Salvadeo SA, D'Angelo A, Fogari E, Ragonesi PD, Ciccarelli L, et al. Rosiglitazone therapy improves insulin resistance parameters in overweight and obese diabetic patients intolerant to metformin. Arch Med Res. 2008;39(4):412–9.
Galle J, Kleophas W, Dellanna F, Schmid VH, Forkel C, Dikta G, et al. Comparison of the effects of pioglitazone versus placebo when given in addition to standard insulin treatment in patients with type 2 diabetes mellitus requiring hemodialysis: results from the PIOren study. Nephron extra. 2012;2(1):104–14.
Grey A, Beckley V, Doyle A, Fenwick S, Horne A, Gamble G, et al. Pioglitazone increases bone marrow fat in type 2 diabetes: results from a randomized controlled trial. Eur J Endocrinol. 2012;166(6):1087–91.
Kaku K. Efficacy and safety of therapy with metformin plus pioglitazone in the treatment of patients with type 2 diabetes: a double-blind, placebo-controlled, clinical trial. Curr Med Res Opin. 2009;25(5):1111–9.
Charpentier G, Halimi S. Earlier triple therapy with pioglitazone in patients with type 2 diabetes. Diabetes Obes Metab. 2009;11(9):844–54.
Negro R, Mangieri T, Dazzi D, Pezzarossa A, Hassan H. Rosiglitazone effects on blood pressure and metabolic parameters in nondipper diabetic patients. Diabetes Res Clin Pract. 2005;70(1):20–5.
Bertrand OF, Poirier P, Rodes-Cabau J, Rinfret S, Title LM, Dzavik V, et al. Cardiometabolic effects of rosiglitazone in patients with type 2 diabetes and coronary artery bypass grafts: a randomized placebo-controlled clinical trial. Atherosclerosis. 2010;211(2):565–73.
Ahren B, Gomis R, Standl E, Mills D, Schweizer A. Twelve- and 52-week efficacy of the dipeptidyl peptidase IV inhibitor LAF237 in metformin-treated patients with type 2 diabetes. Diabetes Care. 2004;27(12):2874–80.
Kikuchi M, Haneda M, Koya D, Tobe K, Onishi Y, Couturier A, et al. Efficacy and tolerability of vildagliptin as an add-on to glimepiride in Japanese patients with type 2 diabetes mellitus. Diabetes Res Clin Pract. 2010;89(3):216–23.
Kaku K, Itayasu T, Hiroi S, Hirayama M, Seino Y. Efficacy and safety of alogliptin added to pioglitazone in Japanese patients with type 2 diabetes: a randomized, double-blind, placebo-controlled trial with an open-label long-term extension study. Diabetes Obes Metab. 2011;13(11):1028–35.
Nowicki M, Rychlik I, Haller H, Warren ML, Suchower L, Gause-Nilsson I. Saxagliptin improves glycaemic control and is well tolerated in patients with type 2 diabetes mellitus and renal impairment. Diabetes Obes Metab. 2011;13(6):523–32.
Seino Y, Fujita T, Hiroi S, Hirayama M, Kaku K. Alogliptin plus voglibose in Japanese patients with type 2 diabetes: a randomized, double-blind, placebo-controlled trial with an open-label, long-term extension. Curr Med Res Opin. 2011;27(Suppl 3):21–9.
Rosenstock J, Aggarwal N, Polidori D, Zhao Y, Arbit D, Usiskin K, et al. Dose-ranging effects of canagliflozin, a sodium-glucose cotransporter 2 inhibitor, as add-on to metformin in subjects with type 2 diabetes. Diabetes Care. 2012;35(6):1232–8.
Ross SA, Rafeiro E, Meinicke T, Toorawa R, Weber-Born S, Woerle HJ. Efficacy and safety of linagliptin 2.5 mg twice daily versus 5 mg once daily in patients with type 2 diabetes inadequately controlled on metformin: a randomised, double-blind, placebo-controlled trial. Curr Med Res Opin. 2012;28(9):1465–74.
Kadowaki T, Kondo K. Efficacy and safety of teneligliptin in combination with pioglitazone in Japanese patients with type 2 diabetes mellitus. J Diab Invest. 2013;4(6):576–84.
Kadowaki T, Kondo K. Efficacy and safety of teneligliptin added to glimepiride in Japanese patients with type 2 diabetes mellitus: a randomized, double-blind, placebo-controlled study with an open-label, long-term extension. Diabetes Obes Metab. 2014;16(5):418–25.
Kim MK, Rhee EJ, Han KA, Woo AC, Lee MK, Ku BJ, et al. Efficacy and safety of teneligliptin, a dipeptidyl peptidase-4 inhibitor, combined with metformin in Korean patients with type 2 diabetes mellitus: a 16-week, randomized, double-blind, placebo-controlled phase III trial. Diabetes Obes Metab. 2015;17(3):309–12.
Kadowaki T, Kondo K, Sasaki N, Miyayama K, Yokota S, Terata R, et al. Efficacy and safety of teneligliptin add-on to insulin monotherapy in Japanese patients with type 2 diabetes mellitus: a 16-week, randomized, double-blind, placebo-controlled trial with an open-label period. Expert Opin Pharmacother. 2017;18(13):1291–300.
Raz I, Chen Y, Wu M, Hussain S, Kaufman KD, Amatruda JM, et al. Efficacy and safety of sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes. Curr Med Res Opin. 2008;24(2):537–50.
Lewin AJ, Arvay L, Liu D, Patel S, von Eynatten M, Woerle HJ. Efficacy and tolerability of linagliptin added to a sulfonylurea regimen in patients with inadequately controlled type 2 diabetes mellitus: an 18-week, multicenter, randomized, double-blind, placebo-controlled trial. Clin Ther. 2012;34(9):1909–19 e15.
Dobs AS, Goldstein BJ, Aschner P, Horton ES, Umpierrez GE, Duran L, et al. Efficacy and safety of sitagliptin added to ongoing metformin and rosiglitazone combination therapy in a randomized placebo-controlled 54-week trial in patients with type 2 diabetes. J Diab. 2013;5(1):68–79.
Gantz I, Chen M, Suryawanshi S, Ntabadde C, Shah S, O'Neill EA, et al. A randomized, placebo-controlled study of the cardiovascular safety of the once-weekly DPP-4 inhibitor omarigliptin in patients with type 2 diabetes mellitus. Cardiovasc Diabetol. 2017;16(1):112.
Charbonnel B, Karasik A, Liu J, Wu M, Meininger G. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone. Diabetes Care. 2006;29(12):2638–43.
Rosenstock J, Brazg R, Andryuk PJ, Lu K, Stein P. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes: a 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Clin Ther. 2006;28(10):1556–68.
Bosi E, Camisasca RP, Collober C, Rochotte E, Garber AJ. Effects of vildagliptin on glucose control over 24 weeks in patients with type 2 diabetes inadequately controlled with metformin. Diabetes Care. 2007;30(4):890–5.
Fonseca V, Schweizer A, Albrecht D, Baron MA, Chang I, Dejager S. Addition of vildagliptin to insulin improves glycaemic control in type 2 diabetes. Diabetologia. 2007;50(6):1148–55.
Garber AJ, Schweizer A, Baron MA, Rochotte E, Dejager S. Vildagliptin in combination with pioglitazone improves glycaemic control in patients with type 2 diabetes failing thiazolidinedione monotherapy: a randomized, placebo-controlled study. Diabetes Obes Metab. 2007;9(2):166–74.
Hermansen K, Kipnes M, Luo E, Fanurik D, Khatami H, Stein P. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin. Diabetes Obes Metab. 2007;9(5):733–45.
Garber AJ, Foley JE, Banerji MA, Ebeling P, Gudbjornsdottir S, Camisasca RP, et al. Effects of vildagliptin on glucose control in patients with type 2 diabetes inadequately controlled with a sulphonylurea. Diabetes Obes Metab. 2008;10(11):1047–56.
Goodman M, Thurston H, Penman J. Efficacy and tolerability of vildagliptin in patients with type 2 diabetes inadequately controlled with metformin monotherapy. Horm Metab Res. 2009;41(5):368–73.
Hollander P, Li J, Allen E, Chen R. Saxagliptin added to a thiazolidinedione improves glycemic control in patients with type 2 diabetes and inadequate control on thiazolidinedione alone. J Clin Endocrinol Metab. 2009;94(12):4810–9.
Jadzinsky M, Pfutzner A, Paz-Pacheco E, Xu Z, Allen E, Chen R. Saxagliptin given in combination with metformin as initial therapy improves glycaemic control in patients with type 2 diabetes compared with either monotherapy: a randomized controlled trial. Diabetes Obes Metab. 2009;11(6):611–22.
Pratley RE, Reusch JE, Fleck PR, Wilson CA, Mekki Q. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin added to pioglitazone in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled study. Curr Med Res Opin. 2009;25(10):2361–71.
Vilsboll T, Rosenstock J, Yki-Jarvinen H, Cefalu WT, Chen Y, Luo E, et al. Efficacy and safety of sitagliptin when added to insulin therapy in patients with type 2 diabetes. Diabetes Obes Metab. 2010;12(2):167–77.
Gomis R, Espadero RM, Jones R, Woerle HJ, Dugi KA. Efficacy and safety of initial combination therapy with linagliptin and pioglitazone in patients with inadequately controlled type 2 diabetes: a randomized, double-blind, placebo-controlled study. Diabetes Obes Metab. 2011;13(7):653–61.
Owens DR, Swallow R, Dugi KA, Woerle HJ. Efficacy and safety of linagliptin in persons with type 2 diabetes inadequately controlled by a combination of metformin and sulphonylurea: a 24-week randomized study. Diab Med. 2011;28(11):1352–61.
Taskinen MR, Rosenstock J, Tamminen I, Kubiak R, Patel S, Dugi KA, et al. Safety and efficacy of linagliptin as add-on therapy to metformin in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled study. Diabetes Obes Metab. 2011;13(1):65–74.
Yang W, Pan CY, Tou C, Zhao J, Gause-Nilsson I. Efficacy and safety of saxagliptin added to metformin in Asian people with type 2 diabetes mellitus: a randomized controlled trial. Diabetes Res Clin Pract. 2011;94(2):217–24.
Barnett AH, Charbonnel B, Donovan M, Fleming D, Chen R. Effect of saxagliptin as add-on therapy in patients with poorly controlled type 2 diabetes on insulin alone or insulin combined with metformin. Curr Med Res Opin. 2012;28(4):513–23.
Bergenstal RM, Forti A, Chiasson JL, Woloschak M, Boldrin M, Balena R. Efficacy and safety of taspoglutide versus sitagliptin for type 2 diabetes mellitus (T-emerge 4 trial). Diab Ther. 2012;3(1):13.
Pan C, Xing X, Han P, Zheng S, Ma J, Liu J, et al. Efficacy and tolerability of vildagliptin as add-on therapy to metformin in Chinese patients with type 2 diabetes mellitus. Diabetes Obes Metab. 2012;14(8):737–44.
Seino Y, Miyata Y, Hiroi S, Hirayama M, Kaku K. Efficacy and safety of alogliptin added to metformin in Japanese patients with type 2 diabetes: a randomized, double-blind, placebo-controlled trial with an open-label, long-term extension study. Diabetes Obes Metab. 2012;14(10):927–36.
Yang W, Guan Y, Shentu Y, Li Z, Johnson-Levonas AO, Engel SS, et al. The addition of sitagliptin to ongoing metformin therapy significantly improves glycemic control in Chinese patients with type 2 diabetes. J Diab. 2012;4(3):227–37.
Barnett AH, Huisman H, Jones R, von Eynatten M, Patel S, Woerle HJ. Linagliptin for patients aged 70 years or older with type 2 diabetes inadequately controlled with common antidiabetes treatments: a randomised, double-blind, placebo-controlled trial. Lancet. 2013;382(9902):1413–23.
Strain WD, Lukashevich V, Kothny W, Hoellinger MJ, Paldanius PM. Individualised treatment targets for elderly patients with type 2 diabetes using vildagliptin add-on or lone therapy (INTERVAL): a 24 week, randomised, double-blind, placebo-controlled study. Lancet. 2013;382(9890):409–16.
Zeng Z, Yang JK, Tong N, Yan S, Zhang X, Gong Y, et al. Efficacy and safety of linagliptin added to metformin and sulphonylurea in Chinese patients with type 2 diabetes: a sub-analysis of data from a randomised clinical trial. Curr Med Res Opin. 2013;29(8):921–9.
Lukashevich V, Del Prato S, Araga M, Kothny W. Efficacy and safety of vildagliptin in patients with type 2 diabetes mellitus inadequately controlled with dual combination of metformin and sulphonylurea. Diabetes Obes Metab. 2014;16(5):403–9.
Wang W, Yang J, Yang G, Gong Y, Patel S, Zhang C, et al. Efficacy and safety of linagliptin in Asian patients with type 2 diabetes mellitus inadequately controlled by metformin: a multinational 24-week, randomized clinical trial. J Diab. 2016;8(2):229–37.
Yang W, Xing X, Lv X, Li Y, Ma J, Yuan G, et al. Vildagliptin added to sulfonylurea improves glycemic control without hypoglycemia and weight gain in Chinese patients with type 2 diabetes mellitus. J Diab. 2015;7(2):174–81.
Ning G, Wang W, Li L, Ma J, Lv X, Yang M, et al. Vildagliptin as add-on therapy to insulin improves glycemic control without increasing risk of hypoglycemia in Asian, predominantly Chinese, patients with type 2 diabetes mellitus. J Diab. 2016;8(3):345–53.
Ahn CH, Han KA, Yu JM, Nam JY, Ahn KJ, Oh TK, et al. Efficacy and safety of gemigliptin, a dipeptidyl peptidase-4 inhibitor, in patients with type 2 diabetes mellitus inadequately controlled with combination treatment of metformin and sulphonylurea: a 24-week, multicentre, randomized, double-blind, placebo-controlled study (TROICA study). Diabetes Obes Metab. 2017;19(5):635–43.
Lee SH, Gantz I, Round E, Latham M, O'Neill EA, Ceesay P, et al. A randomized, placebo-controlled clinical trial evaluating the safety and efficacy of the once-weekly DPP-4 inhibitor omarigliptin in patients with type 2 diabetes mellitus inadequately controlled by glimepiride and metformin. BMC Endocr Disord. 2017;17(1):70.
Shankar RR, Inzucchi SE, Scarabello V, Gantz I, Kaufman KD, Lai E, et al. A randomized clinical trial evaluating the efficacy and safety of the once-weekly dipeptidyl peptidase-4 inhibitor omarigliptin in patients with type 2 diabetes inadequately controlled on metformin monotherapy. Curr Med Res Opin. 2017;33(10):1853–60.
Kadowaki T, Inagaki N, Kondo K, Nishimura K, Kaneko G, Maruyama N, et al. Efficacy and safety of teneligliptin added to canagliflozin monotherapy in Japanese patients with type 2 diabetes mellitus: a multicentre, randomized, double-blind, placebo-controlled, parallel-group comparative study. Diabetes Obes Metab. 2018;20(2):453–7.
Nauck MA, Ellis GC, Fleck PR, Wilson CA, Mekki Q. Efficacy and safety of adding the dipeptidyl peptidase-4 inhibitor alogliptin to metformin therapy in patients with type 2 diabetes inadequately controlled with metformin monotherapy: a multicentre, randomised, double-blind, placebo-controlled study. Int J Clin Pract. 2009;63(1):46–55.
DeFronzo RA, Burant CF, Fleck P, Wilson C, Mekki Q, Pratley RE. Efficacy and tolerability of the DPP-4 inhibitor alogliptin combined with pioglitazone, in metformin-treated patients with type 2 diabetes. J Clin Endocrinol Metab. 2012;97(5):1615–22.
Fonseca V, Staels B, Morgan JD 2nd, Shentu Y, Golm GT, Johnson-Levonas AO, et al. Efficacy and safety of sitagliptin added to ongoing metformin and pioglitazone combination therapy in a randomized, placebo-controlled, 26-week trial in patients with type 2 diabetes. J Diabetes Complicat. 2013;27(2):177–83.
Lavalle-Gonzalez FJ, Januszewicz A, Davidson J, Tong C, Qiu R, Canovatchel W, et al. Efficacy and safety of canagliflozin compared with placebo and sitagliptin in patients with type 2 diabetes on background metformin monotherapy: a randomised trial. Diabetologia. 2013;56(12):2582–92.
Derosa G, Carbone A, D'Angelo A, Querci F, Fogari E, Cicero AF, et al. A randomized, double-blind, placebo-controlled trial evaluating sitagliptin action on insulin resistance parameters and beta-cell function. Expert Opin Pharmacother. 2012;13(17):2433–42.
Derosa G, Ragonesi PD, Carbone A, Fogari E, Bianchi L, Bonaventura A, et al. Vildagliptin added to metformin on beta-cell function after a euglycemic hyperinsulinemic and hyperglycemic clamp in type 2 diabetes patients. Diabetes Technol Ther. 2012;14(6):475–84.
Bosi E, Ellis GC, Wilson CA, Fleck PR. Alogliptin as a third oral antidiabetic drug in patients with type 2 diabetes and inadequate glycaemic control on metformin and pioglitazone: a 52-week, randomized, double-blind, active-controlled, parallel-group study. Diabetes Obes Metab. 2011;13(12):1088–96.
Kothny W, Shao Q, Groop PH, Lukashevich V. One-year safety, tolerability and efficacy of vildagliptin in patients with type 2 diabetes and moderate or severe renal impairment. Diabetes Obes Metab. 2012;14(11):1032–9.
Henry RR, Strange P, Zhou R, et al. Effects of dapagliflozin on 24-hour glycemic control in patients with type 2 diabetes: a randomized controlled trial. Diabetes Technol Ther. 2018;20(11):715–24.
Latva-Rasku A, Honka MJ, Kullberg J, et al. The SGLT2 inhibitor dapagliflozin reduces liver fat but does not affect tissue insulin sensitivity: a randomized, double-blind, placebo controlled study with 8-week treatment in type 2 diabetes patients. Diabetes Care. 2019;42(5):931–7.
Wilding JP, Norwood P, T'Joen C, Bastien A, List JF, Fiedorek FT. A study of dapagliflozin in patients with type 2 diabetes receiving high doses of insulin plus insulin sensitizers: applicability of a novel insulin-independent treatment. Diabetes Care. 2009;32(9):1656–62.
Wilding JP, Ferrannini E, Fonseca VA, Wilpshaar W, Dhanjal P, Houzer A. Efficacy and safety of ipragliflozin in patients with type 2 diabetes inadequately controlled on metformin: a dose-finding study. Diabetes Obes Metab. 2013;15(5):403–9.
Amin NB, Wang X, Jain SM, Lee DS, Nucci G, Rusnak JM. Dose-ranging efficacy and safety study of ertugliflozin, a sodium-glucose co-transporter 2 inhibitor, in patients with type 2 diabetes on a background of metformin. Diabetes Obes Metab. 2015;17(6):591–8.
Weber MA, Mansfield TA, Cain VA, Iqbal N, Parikh S, Ptaszynska A. Blood pressure and glycaemic effects of dapagliflozin versus placebo in patients with type 2 diabetes on combination antihypertensive therapy: a randomised, double-blind, placebo-controlled, phase 3 study. Lancet Diab Endocrinol. 2016;4(3):211–20.
Kario K, Okada K, Kato M, et al. 24-hour blood pressure-lowering effect of an SGLT-2 inhibitor in patients with diabetes and uncontrolled nocturnal hypertension: results from the randomized, placebo-controlled SACRA Study. Circulation. 2018;139(18):2089–97.
Ross S, Thamer C, Cescutti J, Meinicke T, Woerle HJ, Broedl UC. Efficacy and safety of empagliflozin twice daily versus once daily in patients with type 2 diabetes inadequately controlled on metformin: a 16-week, randomized, placebo-controlled trial. Diabetes Obes Metab. 2015;17(7):699–702.
Schumm-Draeger PM, Burgess L, Koranyi L, Hruba V, Hamer-Maansson JE, de Bruin TW. Twice-daily dapagliflozin co-administered with metformin in type 2 diabetes: a 16-week randomized, placebo-controlled clinical trial. Diabetes Obes Metab. 2015;17(1):42–51.
Ishihara H, Yamaguchi S, Nakao I, Okitsu A, Asahina S. Efficacy and safety of ipragliflozin as add-on therapy to insulin in Japanese patients with type 2 diabetes mellitus (IOLITE): a multi-centre, randomized, placebo-controlled, double-blind study. Diabetes Obes Metab. 2016;18(12):1207–16.
Terauchi Y, Tamura M, Senda M, Gunji R, Kaku K. Efficacy and safety of tofogliflozin in Japanese patients with type 2 diabetes mellitus with inadequate glycaemic control on insulin therapy (J-STEP/INS): results of a 16-week randomized, double-blind, placebo-controlled multicentre trial. Diabetes Obes Metab. 2017;19(10):1397–407.
Seino Y, Sasaki T, Fukatsu A, Imazeki H, Ochiai H, Sakai S. Efficacy and safety of luseogliflozin added to insulin therapy in Japanese patients with type 2 diabetes: a multicenter, 52-week, clinical study with a 16-week, double-blind period and a 36-week, open-label period. Curr Med Res Opin. 2018;34(6):981–94.
Ji L, Han P, Liu Y, Yang G, Dieu Van NK, Vijapurkar U, et al. Canagliflozin in Asian patients with type 2 diabetes on metformin alone or metformin in combination with sulphonylurea. Diabetes Obes Metab. 2015;17(1):23–31.
Neal B, Perkovic V, de Zeeuw D, Mahaffey KW, Fulcher G, Ways K, et al. Efficacy and safety of canagliflozin, an inhibitor of sodium-glucose cotransporter 2, when used in conjunction with insulin therapy in patients with type 2 diabetes. Diabetes Care. 2015;38(3):403–11.
Bailey CJ, Gross JL, Pieters A, Bastien A, List JF. Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trial. Lancet. 2010;375(9733):2223–33.
Strojek K, Yoon KH, Hruba V, Elze M, Langkilde AM, Parikh S. Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with glimepiride: a randomized, 24-week, double-blind, placebo-controlled trial. Diabetes Obes Metab. 2011;13(10):928–38.
Bolinder J, Ljunggren O, Kullberg J, Johansson L, Wilding J, Langkilde AM, et al. Effects of dapagliflozin on body weight, total fat mass, and regional adipose tissue distribution in patients with type 2 diabetes mellitus with inadequate glycemic control on metformin. J Clin Endocrinol Metab. 2012;97(3):1020–31.
Henry RR, Murray AV, Marmolejo MH, Hennicken D, Ptaszynska A, List JF. Dapagliflozin, metformin XR, or both: initial pharmacotherapy for type 2 diabetes, a randomised controlled trial. Int J Clin Pract. 2012;66(5):446–56.
Haring HU, Merker L, Seewaldt-Becker E, Weimer M, Meinicke T, Woerle HJ, et al. Empagliflozin as add-on to metformin plus sulfonylurea in patients with type 2 diabetes: a 24-week, randomized, double-blind, placebo-controlled trial. Diabetes Care. 2013;36(11):3396–404.
Haring HU, Merker L, Seewaldt-Becker E, Weimer M, Meinicke T, Broedl UC, et al. Empagliflozin as add-on to metformin in patients with type 2 diabetes: a 24-week, randomized, double-blind, placebo-controlled trial. Diabetes Care. 2014;37(6):1650–9.
Kovacs CS, Seshiah V, Swallow R, Jones R, Rattunde H, Woerle HJ, et al. Empagliflozin improves glycaemic and weight control as add-on therapy to pioglitazone or pioglitazone plus metformin in patients with type 2 diabetes: a 24-week, randomized, placebo-controlled trial. Diabetes Obes Metab. 2014;16(2):147–58.
Leiter LA, Cefalu WT, de Bruin TW, Gause-Nilsson I, Sugg J, Parikh SJ. Dapagliflozin added to usual care in individuals with type 2 diabetes mellitus with preexisting cardiovascular disease: a 24-week, multicenter, randomized, double-blind, placebo-controlled study with a 28-week extension. J Am Geriatr Soc. 2014;62(7):1252–62.
Mathieu C, Ranetti AE, Li D, Ekholm E, Cook W, Hirshberg B, et al. Randomized, double-blind, phase 3 trial of triple therapy with dapagliflozin add-on to saxagliptin plus metformin in type 2 diabetes. Diabetes Care. 2015;38(11):2009–17.
Matthaei S, Bowering K, Rohwedder K, Grohl A, Parikh S. Dapagliflozin improves glycemic control and reduces body weight as add-on therapy to metformin plus sulfonylurea: a 24-week randomized, double-blind clinical trial. Diabetes Care. 2015;38(3):365–72.
Rosenstock J, Hansen L, Zee P, Li Y, Cook W, Hirshberg B, et al. Dual add-on therapy in type 2 diabetes poorly controlled with metformin monotherapy: a randomized double-blind trial of saxagliptin plus dapagliflozin addition versus single addition of saxagliptin or dapagliflozin to metformin. Diabetes Care. 2015;38(3):376–83.
Hadjadj S, Rosenstock J, Meinicke T, Woerle HJ, Broedl UC. Initial combination of empagliflozin and metformin in patients with type 2 diabetes. Diabetes Care. 2016;39(10):1718–28.
Lu CH, Min KW, Chuang LM, Kokubo S, Yoshida S, Cha BS. Efficacy, safety, and tolerability of ipragliflozin in Asian patients with type 2 diabetes mellitus and inadequate glycemic control with metformin: results of a phase 3 randomized, placebo-controlled, double-blind, multicenter trial. J Diab Invest. 2016;7(3):366–73.
Kadowaki T, Inagaki N, Kondo K, Nishimura K, Kaneko G, Maruyama N, et al. Efficacy and safety of canagliflozin as add-on therapy to teneligliptin in Japanese patients with type 2 diabetes mellitus: results of a 24-week, randomized, double-blind, placebo-controlled trial. Diabetes Obes Metab. 2017;19(6):874–82.
Cusi K, Bril F, Barb D, et al. Effect of canagliflozin treatment on hepatic triglyceride content and glucose metabolism in patients with type 2 diabetes. Diabetes Obes Metab. 2019;21(4):812–21.
Fioretto P, Del Prato S, Buse JB, Goldenberg R, Giorgino F, Reyner D, Langkilde AM, Sjöström CD, Sartipy P. DERIVE Study Investigators. Efficacy and safety of dapagliflozin in patients with type 2 diabetes and moderate renal impairment (chronic kidney disease stage 3A): the DERIVE study. Diabetes Obes Metab. 2018;20(11):2532–40.
Han KA, Chon S, Chung CH, et al. Efficacy and safety of ipragliflozin as an add-on therapy to sitagliptin and metformin in Korean patients with inadequately controlled type 2 diabetes mellitus: a randomized controlled trial. Diabetes Obes Metab. 2018;20(10):2408–15.
Shestakova MV, Wilding JPH, Wilpshaar W, et al. A phase 3 randomized placebo-controlled trial to assess the efficacy and safetyofipragliflozin as an add-on therapy to metformin in Russian patients with inadequately controlled type 2 diabetes mellitus. Diabetes Res Clin Pract. 2018;146:240–50.
Yang WY, Ma JH, Li YM, et al. Dapagliflozin as add-on therapy in Asian patients with type 2 diabetes inadequately controlled on insulin with or without oral antihyperglycemic drugs: a randomized controlled trial. J Diab. 2018;10:589–99.
Ferdinand KC, Seman L, Salsali A. Design of a 24-week trial of empagliflozin once daily in hypertensive black/African American patients with type 2 diabetes mellitus. Curr Med Res Opin. 2018;34(2):361–7.
Yale JF, Bakris G, Cariou B, Yue D, David-Neto E, Xi L, et al. Efficacy and safety of canagliflozin in subjects with type 2 diabetes and chronic kidney disease. Diabetes Obes Metab. 2013;15(5):463–73.
Forst T, Guthrie R, Goldenberg R, Yee J, Vijapurkar U, Meininger G, et al. Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes on background metformin and pioglitazone. Diabetes Obes Metab. 2014;16(5):467–77.
Grunberger G, Camp S, Johnson J, Huyck S, Terra SG, Mancuso JP, et al. Ertugliflozin in patients with stage 3 chronic kidney disease and type 2 diabetes mellitus: the VERTIS RENAL randomized study. Diab Ther. 2018;9(1):49–66.
Miller S, Krumins T, Zhou H, et al. Ertugliflozin and sitagliptin co-initiation in patients with type 2 diabetes: the VERTIS SITA randomized study. Diabetes Ther. 2018;9(1):253–68.
Rosenstock J, Frias J, Páll D, et al. Effect of ertugliflozin on glucose control, body weight, blood pressure and bone density in type 2 diabetes mellitus inadequately controlled on metformin monotherapy (VERTIS MET). Diabetes Obes Metab. 2018;20(3):520–9.
Ji L, Liu Y, Miao H, et al. Safety and efficacy of ertugliflozin in Asian patients with type 2 diabetes mellitus inadequately controlled with metformin monotherapy: VERTIS Asia. Diabetes Obes Metab. 2019;21(6):1474–82.
Rosenstock J, Vico M, Wei L, Salsali A, List JF. Effects of dapagliflozin, an SGLT2 inhibitor, on HbA (1c), body weight, and hypoglycemia risk in patients with type 2 diabetes inadequately controlled on pioglitazone monotherapy. Diabetes Care. 2012;35(7):1473–8.
Wilding JP, Woo V, Soler NG, Pahor A, Sugg J, Rohwedder K, et al. Long-term efficacy of dapagliflozin in patients with type 2 diabetes mellitus receiving high doses of insulin: a randomized trial. Ann Intern Med. 2012;156(6):405–15.
Ljunggren O, Bolinder J, Johansson L, Wilding J, Langkilde AM, Sjostrom CD, et al. Dapagliflozin has no effect on markers of bone formation and resorption or bone mineral density in patients with inadequately controlled type 2 diabetes mellitus on metformin. Diabetes Obes Metab. 2012;14(11):990–9.
Barnett AH, Mithal A, Manassie J, Jones R, Rattunde H, Woerle HJ, et al. Efficacy and safety of empagliflozin added to existing antidiabetes treatment in patients with type 2 diabetes and chronic kidney disease: a randomised, double-blind, placebo-controlled trial. Lancet Diab Endocrinol. 2014;2(5):369–84.
Rosenstock J, Jelaska A, Frappin G, Salsali A, Kim G, Woerle HJ, et al. Improved glucose control with weight loss, lower insulin doses, and no increased hypoglycemia with empagliflozin added to titrated multiple daily injections of insulin in obese inadequately controlled type 2 diabetes. Diabetes Care. 2014;37(7):1815–23.
Cefalu WT, Leiter LA, de Bruin TW, Gause-Nilsson I, Sugg J, Parikh SJ. Dapagliflozin’s effects on glycemia and cardiovascular risk factors in high-risk patients with type 2 diabetes: a 24-week, multicenter, randomized, double-blind, placebo-controlled study with a 28-week extension. Diabetes Care. 2015;38(7):1218–27.
Araki E, Onishi Y, Asano M, Kim H, Yajima T. Efficacy and safety of dapagliflozin over 1 year as add-on to insulin therapy in Japanese patients with type 2 diabetes: the DAISY (Dapagliflozin Added to patients under InSulin therapY) trial. Diabetes Obes Metab. 2017;19(4):562–70.
Dagogo-Jack S, Liu J, Eldor R, Amorin G, Johnson J, Hille D, et al. Efficacy and safety of the addition of ertugliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin and sitagliptin: The VERTIS SITA2 placebo-controlled randomized study. Diab Obes Metab. 2018;20(3):530–40.
Yale JF, Xie J, Sherman SE, Garceau C. Canagliflozin in conjunction with sulfonylurea maintains glycemic control and weight loss over 52 weeks: a randomized, controlled trial in patients with type 2 diabetes mellitus. Clin Ther. 2017;39(11):2230–42.e2.
Hattori S. Anti-inflammatory effects of empagliflozin in patients with type 2 diabetes and insulin resistance. Diabetol Metab Syndr. 2018;10:93.
JJabbour SA, Frias JP, Hardy E, et al. Safety and efficacy of exenatide once weekly plus dapagliflozin once daily versus exenatide or dapagliflozin alone in patients with type 2 diabetes inadequately controlled with metformin monotherapy: 52-week results of the DURATION-8 randomized controlled trial. Diabetes Care. 2018;41(10):2136–46.
Kawamori R, Haneda M, Suzaki K, et al. Empagliflozin as add-on to linagliptin in a fixed-dose combination in Japanese patients with type 2 diabetes: glycaemic efficacy and safety profile in a 52-week, randomized, placebo-controlled trial. Diabetes Obes Metab. 2018;20(9):2200–9.
Haering HU, Merker L, Christiansen AV, Roux F, Salsali A, Kim G, et al. Empagliflozin as add-on to metformin plus sulphonylurea in patients with type 2 diabetes. Diabetes Res Clin Pract. 2015;110(1):82–90.
Merker L, Haring HU, Christiansen AV, Roux F, Salsali A, Kim G, et al. Empagliflozin as add-on to metformin in people with type 2 diabetes. Diab Med. 2015;32(12):1555–67.
Bode B, Stenlof K, Harris S, Sullivan D, Fung A, Usiskin K, et al. Long-term efficacy and safety of canagliflozin over 104 weeks in patients aged 55-80 years with type 2 diabetes. Diabetes Obes Metab. 2015;17(3):294–303.
Perkovic V, Jardine MJ, Neal B, et al. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med. 2019;380(24):2295–306.
Neal B, Perkovic V, Mahaffey K W, et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med. 2017;377(7):644–57.
Wiviott SD, Raz I, Sabatine MS. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. Reply. N Engl J Med.2019;380(19):1881–1882.
Vilsboll T, Zdravkovic M, Le-Thi T, Krarup T, Schmitz O, Courreges JP, et al. Liraglutide, a long-acting human glucagon-like peptide-1 analog, given as monotherapy significantly improves glycemic control and lowers body weight without risk of hypoglycemia in patients with type 2 diabetes. Diabetes Care. 2007;30(6):1608–10.
Seino Y, Rasmussen MF, Zdravkovic M, Kaku K. Dose-dependent improvement in glycemia with once-daily liraglutide without hypoglycemia or weight gain: a double-blind, randomized, controlled trial in Japanese patients with type 2 diabetes. Diabetes Res Clin Pract. 2008;81(2):161–8.
Vilsboll T, Brock B, Perrild H, Levin K, Lervang HH, Kolendorf K, et al. Liraglutide, a once-daily human GLP-1 analogue, improves pancreatic B-cell function and arginine-stimulated insulin secretion during hyperglycaemia in patients with type 2 diabetes mellitus. Diab Med. 2008;25(2):152–6.
Miyagawa J, Odawara M, Takamura T, Iwamoto N, Takita Y, Imaoka T. Once-weekly glucagon-like peptide-1 receptor agonist dulaglutide is non-inferior to once-daily liraglutide and superior to placebo in Japanese patients with type 2 diabetes: a 26-week randomized phase III study. Diabetes Obes Metab. 2015;17(10):974–83.
Moretto TJ, Milton DR, Ridge TD, Macconell LA, Okerson T, Wolka AM, et al. Efficacy and tolerability of exenatide monotherapy over 24 weeks in antidiabetic drug-naive patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, parallel-group study. Clin Ther. 2008;30(8):1448–60.
Rosenstock J, Reusch J, Bush M, Yang F, Stewart M. Potential of albiglutide, a long-acting GLP-1 receptor agonist, in type 2 diabetes: a randomized controlled trial exploring weekly, biweekly, and monthly dosing. Diabetes Care. 2009;32(10):1880–6.
Seino Y, Inagaki N, Miyahara H, Okuda I, Bush M, Ye J, et al. A randomized dose-finding study demonstrating the efficacy and tolerability of albiglutide in Japanese patients with type 2 diabetes mellitus. Curr Med Res Opin. 2014;30(6):1095–106.
Nauck MA, Stewart MW, Perkins C, Jones-Leone A, Yang F, Perry C, et al. Efficacy and safety of once-weekly GLP-1 receptor agonist albiglutide (HARMONY 2): 52 week primary endpoint results from a randomised, placebo-controlled trial in patients with type 2 diabetes mellitus inadequately controlled with diet and exercise. Diabetologia. 2016;59(2):266–74.
Grunberger G, Chang A, Garcia Soria G, Botros FT, Bsharat R, Milicevic Z. Monotherapy with the once-weekly GLP-1 analogue dulaglutide for 12 weeks in patients with type 2 diabetes: dose-dependent effects on glycaemic control in a randomized, double-blind, placebo-controlled study. Diab Med. 2012;29(10):1260–7.
Terauchi Y, Satoi Y, Takeuchi M, Imaoka T. Monotherapy with the once weekly GLP-1 receptor agonist dulaglutide for 12 weeks in Japanese patients with type 2 diabetes: dose-dependent effects on glycaemic control in a randomised, double-blind, placebo-controlled study. Endocr J. 2014;61(10):949–59.
Fonseca VA, Alvarado-Ruiz R, Raccah D, Boka G, Miossec P, Gerich JE. Efficacy and safety of the once-daily GLP-1 receptor agonist lixisenatide in monotherapy: a randomized, double-blind, placebo-controlled trial in patients with type 2 diabetes (GetGoal-Mono). Diabetes Care. 2012;35(6):1225–31.
Raz I, Fonseca V, Kipnes M, Durrwell L, Hoekstra J, Boldrin M, et al. Efficacy and safety of taspoglutide monotherapy in drug-naive type 2 diabetic patients after 24 weeks of treatment: results of a randomized, double-blind, placebo-controlled phase 3 study (T-emerge 1). Diabetes Care. 2012;35(3):485–7.
Hollander P, Lasko B, Barnett AH, Bengus M, Kanitra L, Pi-Sunyer FX, et al. Effects of taspoglutide on glycemic control and body weight in obese patients with type 2 diabetes (T-emerge 7 study). Obesity (Silver Spring). 2013;21(2):238–47.
Philip A, Parker V E, Michael S, et al. MEDI0382, a GLP-1 and glucagon receptor dual agonist, in obese or overweight patients with type 2 diabetes: a randomised, controlled, double-blind, ascending dose and phase 2a study. Lancet. 2018;391(10140):2607–18.
Idorn T, Knop FK, Jorgensen MB, Jensen T, Resuli M, Hansen PM, et al. Safety and efficacy of liraglutide in patients with type 2 diabetes and end-stage renal disease: an investigator-initiated, placebo-controlled, double-blind, parallel-group. Randomized Trial Diabetes Care. 2016;39(2):206–13.
Tonneijck L, Smits MM, Muskiet MHA, Hoekstra T, Kramer MHH, Danser AHJ, et al. Acute renal effects of the GLP-1 receptor agonist exenatide in overweight type 2 diabetes patients: a randomised, double-blind, placebo-controlled trial. Diabetologia. 2016;59(7):1412–21.
von Scholten BJ, Persson F, Rosenlund S, Hovind P, Faber J, Hansen TW, et al. The effect of liraglutide on renal function: a randomized clinical trial. Diabetes Obes Metab. 2017;19(2):239–47.
Gao Y, Yoon KH, Chuang LM, Mohan V, Ning G, Shah S, et al. Efficacy and safety of exenatide in patients of Asian descent with type 2 diabetes inadequately controlled with metformin or metformin and a sulphonylurea. Diabetes Res Clin Pract. 2009;83(1):69–76.
Kadowaki T, Namba M, Yamamura A, Sowa H, Wolka AM, Brodows RG. Exenatide exhibits dose-dependent effects on glycemic control over 12 weeks in Japanese patients with suboptimally controlled type 2 diabetes. Endocr J. 2009;56(3):415–24.
Gill A, Hoogwerf BJ, Burger J, Bruce S, Macconell L, Yan P, et al. Effect of exenatide on heart rate and blood pressure in subjects with type 2 diabetes mellitus: a double-blind, placebo-controlled, randomized pilot study. Cardiovasc Diabetol. 2010;9:6.
Nauck MA, Petrie JR, Sesti G, Mannucci E, Courreges JP, Lindegaard ML, et al. A phase 2, randomized, dose-finding study of the novel once-weekly human GLP-1 analog, semaglutide, compared with placebo and open-label liraglutide in patients with type 2 diabetes. Diabetes Care. 2016;39(2):231–41.
Ratner RE, Rosenstock J, Boka G. Dose-dependent effects of the once-daily GLP-1 receptor agonist lixisenatide in patients with type 2 diabetes inadequately controlled with metformin: a randomized, double-blind, placebo-controlled trial. Diab Med. 2010;27(9):1024–32.
Kim D, MacConell L, Zhuang D, Kothare PA, Trautmann M, Fineman M, et al. Effects of once-weekly dosing of a long-acting release formulation of exenatide on glucose control and body weight in subjects with type 2 diabetes. Diabetes Care. 2007;30(6):1487–93.
Umpierrez GE, Blevins T, Rosenstock J, Cheng C, Anderson JH, Bastyr EJ 3rd. The effects of LY2189265, a long-acting glucagon-like peptide-1 analogue, in a randomized, placebo-controlled, double-blind study of overweight/obese patients with type 2 diabetes: the EGO study. Diabetes Obes Metab. 2011;13(5):418–25.
Kaku K, Rasmussen MF, Clauson P, Seino Y. Improved glycaemic control with minimal hypoglycaemia and no weight change with the once-daily human glucagon-like peptide-1 analogue liraglutide as add-on to sulphonylurea in Japanese patients with type 2 diabetes. Diabetes Obes Metab. 2010;12(4):341–7.
Lind M, Hirsch IB, Tuomilehto J, Dahlqvist S, Ahren B, Torffvit O, et al. Liraglutide in people treated for type 2 diabetes with multiple daily insulin injections: randomised clinical trial (MDI Liraglutide trial). BMJ. 2015;351:h5364.
Apovian CM, Bergenstal RM, Cuddihy RM, Qu Y, Lenox S, Lewis MS, et al. Effects of exenatide combined with lifestyle modification in patients with type 2 diabetes. Am J Med. 2010;123(5):468.e9–17.
Ludvik B, Frías J P, Tinahones F J, et al. Dulaglutide as add-on therapy to SGLT2 inhibitors in patients with inadequately controlled type 2 diabetes (AWARD-10): a 24-week, randomised, double-blind, placebo-controlled trial. Lancet Diab Endocrinol. 2018;6(5):370–81.
Dungan KM, Weitgasser R, Perez Manghi F, Pintilei E, Fahrbach JL, Jiang HH, et al. A 24-week study to evaluate the efficacy and safety of once-weekly dulaglutide added on to glimepiride in type 2 diabetes (AWARD-8). Diabetes Obes Metab. 2016;18(5):475–82.
Seino Y, Min KW, Niemoeller E, Takami A. Randomized, double-blind, placebo-controlled trial of the once-daily GLP-1 receptor agonist lixisenatide in Asian patients with type 2 diabetes insufficiently controlled on basal insulin with or without a sulfonylurea (GetGoal-L-Asia). Diabetes Obes Metab. 2012;14(10):910–7.
Ahren B, Leguizamo Dimas A, Miossec P, Saubadu S, Aronson R. Efficacy and safety of lixisenatide once-daily morning or evening injections in type 2 diabetes inadequately controlled on metformin (GetGoal-M). Diabetes Care. 2013;36(9):2543–50.
Riddle MC, Forst T, Aronson R, Sauque-Reyna L, Souhami E, Silvestre L, et al. Adding once-daily lixisenatide for type 2 diabetes inadequately controlled with newly initiated and continuously titrated basal insulin glargine: a 24-week, randomized, placebo-controlled study (GetGoal-duo 1). Diabetes Care. 2013;36(9):2497–503.
Riddle MC, Aronson R, Home P, Marre M, Niemoeller E, Miossec P, et al. Adding once-daily lixisenatide for type 2 diabetes inadequately controlled by established basal insulin: a 24-week, randomized, placebo-controlled comparison (GetGoal-L). Diabetes Care. 2013;36(9):2489–96.
Bolli GB, Munteanu M, Dotsenko S, Niemoeller E, Boka G, Wu Y, et al. Efficacy and safety of lixisenatide once daily vs. placebo in people with type 2 diabetes insufficiently controlled on metformin (GetGoal-F1). Diab Med. 2014;31(2):176–84.
Yu Pan C, Han P, Liu X, Yan S, Feng P, Zhou Z, et al. Lixisenatide treatment improves glycaemic control in Asian patients with type 2 diabetes mellitus inadequately controlled on metformin with or without sulfonylurea: a randomized, double-blind, placebo-controlled, 24-week trial (GetGoal-M-Asia). Diabetes Metab Res Rev. 2014;30(8):726–35.
Rosenstock J, Hanefeld M, Shamanna P, Min KW, Boka G, Miossec P, et al. Beneficial effects of once-daily lixisenatide on overall and postprandial glycemic levels without significant excess of hypoglycemia in type 2 diabetes inadequately controlled on a sulfonylurea with or without metformin (GetGoal-S). J Diabetes Complicat. 2014;28(3):386–92.
Meneilly GS, Roy-Duval C, Alawi H, Dailey G, Bellido D, Trescoli C, et al. Lixisenatide therapy in older patients with type 2 diabetes inadequately controlled on their current antidiabetic treatment: the GetGoal-O randomized trial. Diabetes Care. 2017;40(4):485–93.
Yang W, Min K, Zhou Z, Li L, Xu X, Zhu D, et al. Efficacy and safety of lixisenatide in a predominantly Asian population with type 2 diabetes insufficiently controlled with basal insulin: the GetGoal-L-C randomized trial. Diabetes Obes Metab. 2018;20(2):335–43.
Henry RR, Mudaliar S, Kanitra L, Woloschak M, Balena R. Efficacy and safety of taspoglutide in patients with type 2 diabetes inadequately controlled with metformin plus pioglitazone over 24 weeks: T-Emerge 3 trial. J Clin Endocrinol Metab. 2012;97(7):2370–9.
Vanderheiden A, Harrison L, Warshauer J, Li X, Adams-Huet B, Lingvay I. Effect of adding liraglutide vs placebo to a high-dose lnsulin regimen in patients with type 2 diabetes: a randomized clinical trial. JAMA Intern Med. 2016;176(7):939–47.
Frias JP, Nauck MA, Van J, et al. Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial. Lancet. 2018;392(10160):2180–93.
Russell-Jones D, Vaag A, Schmitz O, Sethi BK, Lalic N, Antic S, et al. Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met+SU): a randomised controlled trial. Diabetologia. 2009;52(10):2046–55.
Zinman B, Gerich J, Buse JB, Lewin A, Schwartz S, Raskin P, et al. Efficacy and safety of the human glucagon-like peptide-1 analog liraglutide in combination with metformin and thiazolidinedione in patients with type 2 diabetes (LEAD-4 Met+TZD). Diabetes Care. 2009;32(7):1224–30.
Ahmann A, Rodbard HW, Rosenstock J, Lahtela JT, de Loredo L, Tornoe K, et al. Efficacy and safety of liraglutide versus placebo added to basal insulin analogues (with or without metformin) in patients with type 2 diabetes: a randomized, placebo-controlled trial. Diabetes Obes Metab. 2015;17(11):1056–64.
Davies MJ, Bain SC, Atkin SL, Rossing P, Scott D, Shamkhalova MS, et al. Efficacy and safety of liraglutide versus placebo as add-on to glucose-lowering therapy in patients with type 2 diabetes and moderate renal impairment (LIRA-RENAL): a randomized clinical trial. Diabetes Care. 2016;39(2):222–30.
Ildiko L, Desouza C V, Lalic K S , et al. A 26-week randomized controlled trial of semaglutide once daily versus liraglutide and placebo in patients with type 2 diabetes suboptimally controlled on diet and exercise with or without metformin. Diabetes Care. 2018;41(9):1926–37.
Zinman B, Hoogwerf BJ, Duran Garcia S, Milton DR, Giaconia JM, Kim DD, et al. The effect of adding exenatide to a thiazolidinedione in suboptimally controlled type 2 diabetes: a randomized trial. Ann Intern Med. 2007;146(7):477–85.
Liutkus J, Rosas Guzman J, Norwood P, Pop L, Northrup J, Cao D, et al. A placebo-controlled trial of exenatide twice-daily added to thiazolidinediones alone or in combination with metformin. Diabetes Obes Metab. 2010;12(12):1058–65.
Wysham C, Blevins T, Arakaki R, Colon G, Garcia P, Atisso C, et al. Efficacy and safety of dulaglutide added onto pioglitazone and metformin versus exenatide in type 2 diabetes in a randomized controlled trial (AWARD-1). Diabetes Care. 2014;37(8):2159–67.
Guja C, Juan P. Frías, Somogyi A , et al. Effect of exenatide QW or placebo, both added to titrated insulin glargine, in uncontrolled type 2 diabetes: the DURATION-7 randomized study. Diab Obes Metab. 2018;20(7):1602–14.
Pozzilli P, Norwood P, Jodar E, Davies MJ, Ivanyi T, Jiang H, et al. Placebo-controlled, randomized trial of the addition of once-weekly glucagon-like peptide-1 receptor agonist dulaglutide to titrated daily insulin glargine in patients with type 2 diabetes (AWARD-9). Diabetes Obes Metab. 2017;19(7):1024–31.
Buse JB, Bergenstal RM, Glass LC, Heilmann CR, Lewis MS, Kwan AY, et al. Use of twice-daily exenatide in basal insulin-treated patients with type 2 diabetes: a randomized, controlled trial. Ann Intern Med. 2011;154(2):103–12.
Buse JB, Han J, Miller S, MacConell L, Pencek R, Wintle M. Addition of exenatide BID to insulin glargine: a post-hoc analysis of the effect on glycemia and weight across a range of insulin titration. Curr Med Res Opin. 2014;30(7):1209–18.
Buse JB, Henry RR, Han J, Kim DD, Fineman MS, Baron AD. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes. Diabetes Care. 2004;27(11):2628–35.
DeFronzo RA, Ratner RE, Han J, Kim DD, Fineman MS, Baron AD. Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. Diabetes Care. 2005;28(5):1092–100.
Kendall DM, Riddle MC, Rosenstock J, Zhuang D, Kim DD, Fineman MS, et al. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea. Diabetes Care. 2005;28(5):1083–91.
Rodbard HW, Ildiko L, John R, et al. Semaglutide added to basal insulin in type 2 diabetes (SUSTAIN 5): a randomized, controlled trial. J Clin Endocrinol Metab. 2018;103(6):2291–301.
Seino Y, Kaneko S, Fukuda S, Osonoi T, Shiraiwa T, Nishijima K, et al. Combination therapy with liraglutide and insulin in Japanese patients with type 2 diabetes: a 36-week, randomized, double-blind, parallel-group trial. J Diab Invest. 2016;7(4):565–73.
Reusch J, Stewart MW, Perkins CM, Cirkel DT, Ye J, Perry CR, et al. Efficacy and safety of once-weekly glucagon-like peptide 1 receptor agonist albiglutide (HARMONY 1 trial): 52-week primary endpoint results from a randomized, double-blind, placebo-controlled trial in patients with type 2 diabetes mellitus not controlled on pioglitazone, with or without metformin. Diabetes Obes Metab. 2014;16(12):1257–64.
Weinstock RS, Guerci B, Umpierrez G, Nauck MA, Skrivanek Z, Milicevic Z. Safety and efficacy of once-weekly dulaglutide versus sitagliptin after 2 years in metformin-treated patients with type 2 diabetes (AWARD-5): a randomized, phase III study. Diabetes Obes Metab. 2015;17(9):849–58.
Davies MJ, Bergenstal R, Bode B, Kushner RF, Lewin A, Skjoth TV, et al. Efficacy of liraglutide for weight loss among patients with type 2 diabetes: the SCALE diabetes randomized clinical trial. JAMA. 2015;314(7):687–99.
Pinget M, Goldenberg R, Niemoeller E, Muehlen-Bartmer I, Guo H, Aronson R. Efficacy and safety of lixisenatide once daily versus placebo in type 2 diabetes insufficiently controlled on pioglitazone (GetGoal-P). Diabetes Obes Metab. 2013;15(11):1000–7.
Hernandez AF, Green JB, Janmohanmed S, D'Agostino RB Sr, Granger CB, Jones NP, et al. Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trail. Lancet. 2018;392(10157):1519–29.
Ahren B, Johnson SL, Stewart M, Cirkel DT, Yang F, Perry C, et al. HARMONY 3: 104-week randomized, double-blind, placebo- and active-controlled trial assessing the efficacy and safety of albiglutide compared with placebo, sitagliptin, and glimepiride in patients with type 2 diabetes taking metformin. Diabetes Care. 2014;37(8):2141–8.
Marso SP, Bain SC, Consoli A, Eliaschewitz FG, Jodar E, Leiter LA, et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2016;375(19):1834–44.
Home PD, Shamanna P, Stewart M, Yang F, Miller M, Perry C, et al. Efficacy and tolerability of albiglutide versus placebo or pioglitazone over 1 year in people with type 2 diabetes currently taking metformin and glimepiride: HARMONY 5. Diabetes Obes Metab. 2015;17(2):179–87.
Holman RR, Bethel MA, Mentz RJ, Thompson VP, Lokhnygina Y, Buse JB, et al. Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2017;377(13):1228–39.
Marso SP, Daniels GH, Brown-Frandsen K, Kristensen P, Mann JF, Nauck MA, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2016;375(4):311–22.
Perucca E, Wiebe S. Not all that glitters is gold: a guide to the critical interpretation of drug trials in epilepsy. Epilepsia Open. 2016;1(1):1–13.
Asmar R, Safar M, Queneau P. Evaluation of the placebo effect and reproducibility of blood pressure measurement in hypertension. Am J Hypertens. 2001;14:546–52.
Ajala O, English P, Pinkney J. Systematic review and meta-analysis of different dietary approaches to the management of type 2 diabetes. Am J Clin Nutr. 2013;97:505–16.
Franz MJ, Boucher JL, Green-Pastors J, Powers MA. Evidence-based nutrition practice guidelines for diabetes and scope and standards of practice. J Am Diet Assoc. 2008;108(Suppl. 1):S52–8.
Franz MJ, Powers MA, Leontos C, et al. The evidence for medical nutrition therapy for type 1 and type 2 diabetes in adults. J Am Diet Assoc. 2010;110:1852–89.
Thomas DE, Elliott EJ, Naughton GA. Exercise for type 2 diabetes mellitus. Cochrane Database Syst Rev. 2006;3:CD002968.
Snowling NJ, Hopkins WG. Effects of different modes of exercise training on glucose control and risk factors for complications in type 2 diabetic patients: a meta-analysis. Diabetes Care. 2006;29:2518–27.
Umpierre D, Ribeiro PAB, Kramer CK, et al. Physical activity advice only or structured exercise training and association with HbA1c levels in type 2 diabetes: a systematic review and meta-analysis. JAMA. 2011;305:1790–9.
Lo R, Lo B, Wells E, et al. The development and evaluation of a computer-aided diabetes education program. Aust J Adv Nurs. 1996;13:19–27.
Fernando D. Knowledge about diabetes and metabolic control in diabetic patients. Ceylon Med J. 1993;38:18–21.
de Wit HM, Te Groen M, Rovers MM, et al. The placebo response of injectable GLP-1 receptor agonists versus oral DPP-4 inhibitors and SGLT-2 inhibitors: a systematic review and meta-analysis. Br J Clin Pharmacol. 2016;82(1):301–14.
Weimer K, Colloca L, Enck P. Age and sex as moderators of the placebo response - an evaluation of systematic reviews and meta-analyses across medicine. Gerontology. 2015;61(2):97–108.
Enck P, Klosterhalfen S. Does sex/gender play a role in placebo and nocebo effects? Conflicting Evidence From Clinical Trials and Experimental Studies. Front Neurosci. 2019;13:160. https://doi.org/10.3389/fnins.2019.00160.
Zhang W, Robertson J, Jones AC, et al. The placebo effect and its determinants in osteoarthritis: meta-analysis of randomised controlled trials. Ann Rheum Dis. 2008;67(12):1716–23.
Chen X, Zou K, Abdullah N, et al. The placebo effect and its determinants in fibromyalgia: meta-analysis of randomised controlled trials. Clin Rheumatol. 2017;36(7):1623–30.
Grelotti DJ, Kaptchuk TJ. Placebo by proxy. BMJ. 2011;343:d4345.
Acknowledgements
We thank the doctors, nurses, and technicians for their practical work during the study at Department of Endocrinology and Metabolism in Peking University People’s Hospital.
Funding
This study was supported by the National Natural Science Foundation of China (No.81970708, No.81970698, and No.81900805) and National Key Research and Development Program (No.2016YFC1304901) of China. The funding organization had no role in the study design, data collection or analysis, interpretation of the data, and decision to approve publication of the finished manuscript.
Author information
Authors and Affiliations
Contributions
LJ and XC conceptualized this study and designed the systematic review protocol; CL, WY, FL, and NL performed the study selection and data extraction; CL and XC performed the statistical analyses; CL and XC prepared the outlines and wrote the manuscript. All authors contributed to the critical revision of manuscript drafts. All authors read and approved the final manuscript.
Corresponding authors
Ethics declarations
Ethics approval and consent to participate
Not applicable.
Consent for publication
Not applicable.
Competing interests
Linong Ji has received fees for lecture presentations and consulting fees from AstraZeneca, Merck, Novartis, Novo Nordisk, Lilly, Roche, Sanofi-Aventis and Takeda, and grants/research support from AstraZeneca, Merck, Novartis, Novo Nordisk and Sanofi-Aventis; there were no other relationships or activities that could appear to have influenced the submitted work. All authors have completed the ICMJE uniform disclosure form at www.icmje.org/coi_disclosure.pdf (available on request from the corresponding author) and declare no support from any organization for the submitted work other than that described above.
Additional information
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Supplementary information
Additional file 1: Table S1.
Baseline characteristics of included RCT studies with type 1 diabetes. Table S2. Baseline characteristics of included RCT studies with type 2 diabetes. Table S3. Risk of bias of included RCT studies with type 1 diabetes. Table S4. Risk of bias of included RCT studies with type 2 diabetes. Table S5. Baseline characteristics by placebo response with HbA1c and weight change. Figure S1. Flowchart of the study. Figure S2. Egger’s test for trials with type 1 diabetes. Figure S3. Egger’s test for trials with type 2 diabetes. Figure S4. Placebo response stratified by patient age in type 1 diabetes mellitus. Figure S5. Placebo response stratified by patient age in type 2 diabetes mellitus. Figure S6. Placebo response stratified by male percentage in type 2 diabetes mellitus. Figure S7. Placebo response stratified by male percentage in type 1 diabetes mellitus. Figure S8. Placebo response stratified by baseline BMI in type 2 diabetes mellitus. Figure S9. Placebo response stratified by baseline BMI in type 1 diabetes mellitus. Figure S10. Placebo response stratified by baseline HbA1c in type 2 diabetes mellitus. Figure S11. Placebo response stratified by baseline HbA1c in type 1 diabetes mellitus. Figure S12. Placebo response stratified by diabetes duration in type 1 diabetes mellitus. Figure S13. Placebo response stratified by diabetes duration in type 2 diabetes mellitus. Figure S14. Placebo response stratified by study duration in type 1 diabetes mellitus. Figure S15. Placebo response stratified by study duration in type 2 diabetes mellitus. Figure S16. Placebo response stratified by publication year in type 1 diabetes mellitus. Figure S17. Placebo response stratified by publication year in type 2 diabetes mellitus.
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
About this article
Cite this article
Lin, C., Cai, X., Yang, W. et al. Age, sex, disease severity, and disease duration difference in placebo response: implications from a meta-analysis of diabetes mellitus. BMC Med 18, 322 (2020). https://doi.org/10.1186/s12916-020-01787-4
Received:
Accepted:
Published:
DOI: https://doi.org/10.1186/s12916-020-01787-4